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ABSTRACT 
DEVELOPMENT AND VALIDATION OF PREDICTIVE RISK AND MULTIPLE 
CRITERIA DECISION ANALYSIS MODELS TO EVALUATE CARDIOVASCULAR 
OUTCOMES AMONG CANCER PATIENTS 
 
By Purva N. Parab, B.Pharm, M.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at 
Virginia Commonwealth University 
Virginia Commonwealth University, 2020 
Advisor: Pramit A. Nadpara, Ph.D. 
Assistant Professor, Department of Pharmacotherapy & Outcomes Science 
Objective: The objectives of our study were to characterize the study population with 
cancer and  cardiovascular diseases (CVD) both as compared to those without and to 
build a predictive model using machine learning (ML) algorithms that can predict the risk 
of CVD in cancer patients. In addition, our objective was also to evaluate characteristics 
associated with cardiotoxic adverse events of breast cancer therapies and develop a 
multiple criteria decision analysis (MCDA) model to conduct benefit-risk assessment of 
breast cancer therapy regimens. Methods: We used Medical Expenditure Panel Survey 
(MEPS) and FDA Adverse Events Reporting System (FAERS) 2005-2015 files along with 
literature evidence for our study. We used MEPS database to train our predictive models 
using ML algorithms such as random forest (RF), gradient boosting and deep learning and 
compared these to standard regression models. Separate predictive models were built for 
chronic and acute CVD. We characterized the population with both cancer and CVD and 
those with cancer therapy associated cardiotoxic adverse events using multinomial logistic 
models . FAERS and literature evidence were also used to build the MCDA model to rank 
the breast cancer therapy regimens given the benefits and the risks involved in the 
treatment alternatives. Results: Our study sample consisted of 44,217 cancer patients 
xv 
 
identified using MEPS 2005-2015 files out of which 12,339 (28.7%) patients were also  
diagnosed with CVD. Age, marital status, education and employment status were the 
sociodemographic characteristics that differed significantly across cancer patients with 
and without CVD.  We observed that most of the ML models for chronic (RF c-statistic: 
0.9872, gradient boosting c-statistic: 0.7608, deep learning c-statistic: 0.7662) and acute 
CVD (RF c-statistic: 0.9738, gradient boosting c-statistic: 0.7853, deep learning c-statistic: 
0.8267) were more accurate than the standard regression models for chronic (standard 
regression model c-statistic: 0.7641, GLM net model c-statistic: 0.7349) and acute 
(standard regression model c-statistic: 0.7534, GLM net model c-statistic: 0.7853) CVD. 
We then used the most accurate RF model to build a web-based application that could 
predict CVD risk. We then identified 35,630,544 breast cancer patients using FAERS 
dataset. Our findings suggest that breast cancer patients receiving targeted therapies were 
more likely to be diagnosed with CVD as compared to those who were receiving 
conventional therapies (OR = 1.213, 95% CI = 1.180, 1.247). On conducting MCDA, we 
found that the breast cancer therapy regimen 3 with trastuzumab, cyclophosphamide/ 
carboplatin and a taxane (paclitaxel/ docetaxel) was the most preferred therapy alternative 
given the benefits and the risks associated with each of the alternatives. Conclusion: Our 
study thus evaluated the use of newer analytical techniques such as ML algorithms and 
MCDA to evaluate certain outcomes. Our study suggests that ML algorithms were more 
accurate in predicting CVD risk in cancer patients. In addition, our MCDA model suggested 
that the breast cancer therapy regimen with trastuzumab, cyclophosphamide/ carboplatin 
and a taxane was the most preferred alternative considering the survival and adverse 
events benefits and risks.
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CHAPTER 1: INTRODUCTION 
BACKGROUND: 
Cancer is one of the most prevalent diseases in the country.1 It has been listed as 
one of the priority conditions by the Agency for Healthcare Research and Quality (AHRQ). 
The mean survival rate of cancer patients is around 67%.1 The financial burden of cancer 
survivors is high too. The AHRQ estimates that the direct medical costs for cancer in the 
US in 2014 were $87.7 billion. On an average, cancer patients pay around $3664 to $8115 
out of pocket annually.2 Cancer patients incur significant indirect costs as well. Considering 
lost productivity value, the human capital approach is estimated to increase from $115.8 
billion in 2000 to $147.6 billion in 2020, a 27.5% increase due only to population growth 
and aging.3 Thus, along with the direct costs, cancer patients have financial burden due 
to significant indirect costs and loss of productivity as well. Comorbidities associated with 
the cancer condition are one of the major reasons for increased financial burden and a 
reduced quality of life.4  
Cardiovascular diseases have been identified as one of the most commonly 
associated comorbidities with cancer patients.5 Cardiovascular diseases (CVD) and 
cancer are the two leading causes of death worldwide.6 They further increase the burden 
on patients if CVD occurs as a comorbidity along with cancer. In cancer patients, the CVD 
mortality rate has increased by 20-30% in recent years, whereas the cancer mortality rate 
has decreased by 20-30%.7 This makes CVD an even bigger concern in cancer patients. 
CVD and cancer share various similarities and possible interactions, including a number 
of similar risk factors like age, tobacco use, diet and lack of physical activity.8 Other than 
the lifestyle risk factors, there are also certain cancer therapies that put patients at a higher 
risk of developing CVD. There have been certain cancer therapies such as 5-fluorouracil, 
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taxanes, cyclophosphamides, trastuzumab, tamoxifen, bevacizumab and certain 
anthracyclines that are proven to be very cardiotoxic.9 In addition to the existing therapies, 
novel anticancer therapeutics associated with higher survival outcomes are also 
associated with a higher cardiotoxic potential making the cardiovascular implications of 
cancer therapies increasingly important.10 Other than targeted therapies, radiotherapy also 
impacts cardiac health and leads to certain cardiotoxicities.10,11 Building a predictive model 
including cancer therapies and cancer type along with lifestyle factors would make 
predicting CVD risk in cancer patients more accurate. With increasing number of 
predictors, the accuracy of standard regression model goes on decreasing due to added 
variance. As the variance increases the standard error increases as well further reducing 
the accuracy pf the regression model. Predictive models using machine learning (ML) 
algorithms can incorporate a very high number of predictors in the model and  predict the 
risk of CVD better.12,13 In addition, CVD has  been identified as one of the leading causes 
of mortality among cancer patients.14 There have been certain studies in the field of cardio-
oncology looking at strategies for management of CVD risk for such cardiac events and 
certain clinical outcomes leading to a need for developing cardio-oncology guidelines.15–
19 Currently, these guidelines are continuously revised by the American College of 
Cardiology.20 CVDs identified along with cancer are coronary artery disease, valvular heart 
disease, heart failure and arrhythmias. Identifying the risk of these CVD conditions in 
cancer patients would help in managing the condition more efficiently.21 Due to the 
increasing reports of cardiotoxicity associated with the newer cancer drugs in the market, 
there has been a growing interest in ways to prevent the cardiovascular events and 
manage cardiovascular health of cancer patients. There are studies conducted in literature 
3 
 
looking at the risk of CVD in cancer patients and strategies to contain the risk. Lifestyle 
factors, certain drug combinations, evidence-based medicine, adherence to CVD 
medications and higher utilization of CVD screening services are some of the strategies 
suggested to reduce the risk of CVD among cancer patients.15,16 Studies looking at 
cardiovascular outcomes in cancer patients are summarized below.  
LITERATURE REVIEW: 
Search strategy and literature summary evaluating the CVD risk associated with 
cancer patients using the conventional regression approach:  
A literature review was conducted using PubMed/Medline to summarize the existing 
evidence with respect to cardiovascular outcomes among patients with cancer. Risk for 
cardiovascular diseases (CVD) among patients with cancer and the benefit-risk tradeoff 
between survival and cardiotoxic outcomes associated with cancer therapies were the 
outcomes that were assessed for in the literature. The following search strategy using a 
combination of MeSH terms was used: (((((((("Cardiovascular Diseases"[Mesh]) AND 
("Cardiovascular Diseases/adverse effects"[Mesh] OR "Cardiovascular 
Diseases/complications"[Mesh] OR "Cardiovascular Diseases/drug therapy"[Mesh] OR 
"Cardiovascular Diseases/epidemiology"[Mesh] OR "Cardiovascular 
Diseases/mortality"[Mesh] OR "Cardiovascular Diseases/organization and 
administration"[Mesh] OR "Cardiovascular Diseases/prevention and control"[Mesh] OR 
"Cardiovascular Diseases/radiotherapy"[Mesh] OR "Cardiovascular Diseases/statistics 
and numerical data"[Mesh] ))) AND "Neoplasms"[Majr]) AND humans) AND English)) AND 
observational studies)  The titles and abstracts were then screened for their eligibility using 
the following inclusion/exclusion criteria. 
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We included studies that report cardiovascular risk/ mortality among patients with 
cancer or cancer survivors. We also included studies that looked at interventions to reduce 
the risk of cardiovascular conditions in patients with cancer and reported these outcomes. 
We only included studies that were conducted in humans and published in English. We 
excluded studies that focused on cancer outcomes rather than cardiovascular outcomes. 
We also excluded studies that were not looking at cardiovascular conditions as a cancer 
comorbidity. We excluded studies that only reported clinical/ physiological outcomes and 
not any other health outcomes. We excluded studies conducted in pediatric population 
and those that were only narrative reviews 
 The search strategy resulted into 527 studies. On applying the inclusion/exclusion 
criteria, 513 articles were excluded. The final literature review included 15 studies.22-36 
Figure 1 below includes a PRISMA flowchart of studies that were included in the literature 
review. All the studies in literature have been published post 2009 which coincides with 
the timeline of majority of targeted therapies booming in the market. The number of studies 
looking at cardiovascular conditions in patients with cancer has increased in the recent 
past. 
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Figure 1: PRISMA Flowchart of Literature Review 
 
Table 1 below summarizes the studies that were included in the literature review. 
There were 15 studies that were summarized for the literature review to identify the gaps 
in the literature. Majority of these studies have either looked at one specific type of cancer 
or have looked at cardiotoxicity associated with one specific cancer therapy.  
 
 
 
Total results through databases searching (n= 527) 
Titles and abstracts reviewed for eligibility  (n=197)  
Studies included (n= 15) 
Remove duplicates (n=17) 
Articles excluded (n=183): 
Only looked at diagnostic 
tools (n=37) 
Focusing on cancer 
outcomes (n=83) 
Not the required outcomes 
(n=46) 
Narrative reviews (n=17) 
 
Articles screened for eligibility (n=510) 
Article excluded (n=313): 
Study sample was not 
appropriate (animal studies, 
not cancer population, not 
looking at CVD as a 
comorbidity) 
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Table 1: Summary of Literature Review 
 
Study Study Objective 
Sturgeon et al., 201922 To characterize CVD mortality risk for multiple cancer sites, with 
respect to (i) continuous calendar year, (ii) age at diagnosis, and 
(iii) follow-up time after diagnosis 
Winther et al., 201823 To examine the risk of CVD among cancer survivors with diabetes 
Pajamaki et al., 201824 To evaluate long-term cardiovascular morbidity and mortality in 
patients treated for differentiated thyroid cancer (DTC) 
Berkman et al., 201725 To assess racial differences in 20-year cardiovascular mortality risk 
among cancer survivors 
Grazziotin et al., 201726 To measure the incidence of trastuzumab-related cardiotoxicity in 
patients with breast cancer 
Khosrow-Khavar et al., 
201727 
To determine the association of aromatase inhibitors with the 
increased risk of cardiovascular events 
Santoni et al., 201728 To evaluate the incidence and relative risk (RR) of developing all-
grade and high-grade cardiotoxicity in cancer patients receiving 
targeted agents  
Armenian et al., 201629 To examine the impact of cardiovascular risk factors in survivors of 
adult-onset cancer 
Bhakta et al., 201630 To estimate the cumulative burden of cardiovascular mortality in 
survivors of Hodgkin’s lymphoma 
Okoye et al., 201631 To quantify CVD risk and receipt of primary preventive care among 
patients with head and neck squamous cell carcinoma treated with 
radiotherapy or chemoradiotherapy  
O’Farrell et al., 201532 To examine the association between risk of CVD and the duration 
and type of androgen-deprivation therapy in men with advanced 
prostate cancer 
Hesselink et al., 201333 To study the risk of CVD mortality in patients with advanced thyroid 
carcinoma 
Mulrooney et al., 200934 To assess the incidences and risks of cardiac outcomes in cancer 
survivors 
Efstathiou et al., 200935 To assess the relationship between cardiovascular mortality and 
androgen deprivation therapy for locally advanced prostate cancer 
patients 
Tsai et al., 200736 To investigate the association between androgen deprivation 
therapy (ADT) and the risk of cardiovascular mortality 
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Studies conducted by Grazziotin et al.,26 Khosrow-Khavar et al.,27 Santoni et al.,28 
Okoye et al.,31 O’Farrell et al.,32 Mulrooney et al.,34 Efstathiou et al.35 and Tsai et al.36 
mainly looked at one specific cancer treatment related cardiotoxicity or cardiac events. 
Pajamaki et al.,24 Bhakta et al.30 and Hesselink et al.33 looked at a small sample size of 
one specific cancer type. There were only four studies conducted by Sturgeon et al.,22 
Winther et al.,23 Berkman et al.,25 and Armenian et al.29 that looked at the overall 
cardiovascular risk/ mortality risk in cancer survivors. 
 Grazziotin et al., suggested that the incidence of trastuzumab-related cardiotoxicity 
in patients with metastatic breast cancer patients was 75% whereas in early stage breast 
cancer patients was 45.7%. This study was however restricted to trastuzumab-related 
cardiotoxicity in cancer patients.26  
Khosrow-Khavar et al. conducted a meta-analysis looking at the cardiotoxicity 
associated with aromatase inhibitors and tamoxifen in postmenopausal women with breast 
cancer. The study found that there was a 19% increased risk of cardiovascular events 
associated with aromatase inhibitors as compared to those using Tamoxifen. The results 
were also suggestive of a small protective effect of Tamoxifen.27   
Santoni et al., conducted a meta-analysis of available clinical trials looking at the 
incidence and relative risks of developing cardiotoxicities in cancer patients receiving 
targeted therapies. The highest relative risk (RR) of high-grade cardiac events was 
observed in Vandetinib (RR = 7.71). Grouping by drug category, highest risk of 
cardiotoxicity was associated with anti-VEGFR-TKIs (RR = 5.62). Targeted agents were 
correlated with a significant increase in the risk of cardiotoxicity. The study was restricted 
to patients receiving targeted therapies and cardiotoxicities associated with these.28  
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Okoye et al. looked at quantifying risk factors of CVD among head and neck 
squamous cell carcinoma patients receiving radiotherapy or chemoradiotherapy. 
Hypertension, smoking and diabetes were the comorbidities that were identified as the 
most prevalent CVD risk factors. This study however only focused on a very small sample 
of head and neck cancers receiving radiotherapy and focused majorly on the risk factors 
of CVD.31  
O’Farrell et al. looked at the association of androgen deprivation therapy (ADT) with 
the risk and timing of CVD in men with prostate cancer. CVD risk was highest during the 
first 6 months of ADT in men who experienced two or more cardiovascular events before 
therapy with a Hazard Ratio (HR) of 1.91.32  
Mulrooney et al. looked at the incidence rates of cardiac outcomes among adult 
cancer survivors. Higher hazard ratios (HR) were associated with congestive heart failure 
(HR = 5.9), myocardial infarction (HR = 5.0), pericardial disease (HR = 6.3) and valvular 
abnormalities (HR = 4.8) in cancer survivors as compared to those without cancer. The 
study also focused mainly on the association of cardiac events with the exposure to cancer 
therapies such as dose of anthracyclines and the extent of radiation exposure. Higher 
doses and exposures were associated with worse cardiac events. This study was however 
restricted to those who had a cancer diagnosis under the age of 21years.34  
Efstathiou et al. and Tsai et al. looked at cardiovascular mortality after ADT. The 
prior study was conducted in patients with localized cancer whereas the later was in 
patients with locally advanced cancer. In the study conducted by Efstathiou et al. the use 
of ADT was significantly associated with increased risk of cardiovascular mortality (HR = 
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2.6). In the later study however, there was no significant increase in treatment-related 
cardiovascular mortality.35,36  
All of these studies have majorly only focused on cancer therapy related 
cardiotoxicities. There have been three studies focusing only on Hodgkin lymphoma and 
thyroid cancer. Bhakta et al. conducted a study assessing the cumulative burden of 
cardiovascular morbidity in Hodgkin lymphoma survivors. The study suggested that at 
50years of age, the cumulative incidence of survivors experiencing at least one grade 3-5 
(more severe) cardiovascular condition was 45.5%. Myocardial infarction was one of the 
major contributors to the excess cardiovascular burden.30  
Pajamaki et al. and Hesselink et al. looked at cardiovascular mortality and morbidity 
in thyroid cancer patients. Both the studies reported similar findings, where patients with 
thyroid cancer reported a higher cardiovascular morbidity as compared to those without 
cancer. Pajamaki et al. reported a higher HR of 1.16 associated with morbidity due to any 
CVD event, whereas a lower HR of 0.73 associated with cardiovascular mortality in thyroid 
cancer patients.24 Hesselink et al. reported increased risk of cardiovascular mortality (HR 
= 3.35) among patients with thyroid cancer. The results with respect to cardiovascular 
mortality in specific cancers are thus inconclusive.33  
Sturgeon et al, suggested in their study that CVD mortality risk was highest in 
survivors diagnosed at <35 years of age with the risk being highest within first year after 
cancer diagnosis (standardized mortality ratio = 3.93, 95% confidence intervals = 3.89-
3.97). This risk remained elevated throughout follow-up compared to general population. 
This study however, only focused on CVD mortality rather than CVD diagnosis risk. In 
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addition, the only factors studied to evaluate the association were age at diagnosis and 
follow-up after diagnosis.22  
Winther et al., suggested that compared to patients without cancer, those with 
cancer are 3.6 times more likely to develop a cardiovascular event. This hazard of 
cardiovascular event is even higher (HR = 8.7) in patients with both cancer and diabetes 
as compared to those without cancer and diabetes. Comorbidities thus add to the burden 
of CVD in patients with cancer.23  
Berkman et al. looked at racial differences in 20-year cardiovascular mortality risk 
in cancer survivors. Black survivors had higher risks for CVD mortality (HR = 2.13) 
compared to white survivors. The increased risk of CVD persisted at 5-years (HR = 2.38) 
and 20-years (HR = 2.31).25  
Armenian et al. examined the impact of cardiovascular risk factors (hypertension, 
diabetes, dyslipidemia) on long-term CVD risk in cancer survivors. Cancer survivors with 
two or more risk factors had the highest risk (incidence rate ratio = 1.83) of CVD when 
compared to noncancer controls. The magnitude of CVD risk varied depending on the 
number of cardiovascular risk factors present. This was the most relevant article for our 
research since it looked at multiple cancers and examined the impact of multiple factors 
on the risk of CVD in cancer patients.29  
Gaps in the literature: 
There are several studies in the literature that have looked at the risk of 
cardiovascular diseases among cancer patients. Majority of these studies have focused 
only on cardiotoxicities associated with specific cancer therapies or have been restricted 
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to a single type of cancer. The studies that looked at multiple cancers and CVD risk factors 
have also focused majorly on one of the risk factors, such as comorbidities, racial 
background or a finite number of CVD risk factors. Thus, it has been established in the 
literature that independently there are multiple risk factors including lifestyle, 
sociodemographic and certain therapy related characteristics that put cancer patients at a 
higher risk of CVD as compared to general population. There has not been an attempt to 
build a predictive risk model which could predict the risk of CVD in cancer patients by  
incorporating all of these factors and their interactions. There is not a clear understanding 
of CVD risk in cancer population on considering all the risk factors and their interactions. 
These predictive models could help in assessing the CVD risk in cancer population  more 
accurately than the standard regression techniques. CVD is becoming a major concern 
among patients with cancer due to high CVD mortality and morbidity rates. A machine 
learning (ML) model in this case would be very beneficial. In addition, there has not been 
an attempt to build a benefit-risk model to account for survival and cardiotoxic outcomes 
of cancer therapies. Accounting for these together in a model would help in assigning a 
value to each therapy and guide the decision-making process. 
RATIONALE: 
 As mentioned earlier, there is not a clear understanding of CVD risk in cancer 
population on a more generalizable scale. There is still a lack of a predictive risk model 
which could incorporate all of these risk factors in a single model and predict the future 
risk of CVD. It has been established in the literature that there are multiple shared risk 
factors including lifestyle, sociodemographic and certain therapy related characteristics 
that put cancer patients at a higher risk of CVD as compared to general population. 
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Machine learning algorithms have proven to be more accurate and precise in situations 
where the number of predictors and interactions within these are large. There are only two 
studies that looked at predicting clinical deterioration (cardiac arrest) or cardiotoxicity in 
cancer patients using the machine learning approach.37,38 These have however looked at 
a very small sample of a specific cancer type and have not incorporated appropriate 
algorithms that could handle interactions within predictors. These have also looked at a 
specific CVD outcome as opposed to the overall CVD risk in cancer patients. CVD is 
becoming a major concern among patients with cancer due to high CVD mortality and 
morbidity rates. Building a predictive risk model by considering majority of predictors would 
help in quantifying the probability of getting diagnosed with CVD better. An understanding 
of the underlying probability of CVD risk beforehand is necessary to tailor interventions 
and manage patients more efficiently. However, the studies so far have used a simpler 
approach to estimate the risk of CVD in cancer patients. As seen from the above literature, 
there is also a lack of evidence of studies that incorporate the benefits and risks of cancer 
therapies together in a model to assign values and make the decision process more 
transparent. Targeted therapies as suggested are associated with a higher survival as well 
as a higher cardiotoxic potential which makes choosing the therapy alternative difficult. 
Most of these targeted therapies associated with a higher survival and cardiotoxic profile 
are used in breast cancer patients. Most of the clinical studies conducted looking at these 
outcomes have also been in breast cancer patients. We would thus assume that breast 
cancer therapies would have the highest benefit-risk trade off and restrict the Multiple 
Criteria Decision Analysis (MCDA) model to have breast cancer therapies as alternatives. 
Current studies have only looked at patient preferences for treatment outcomes, there are 
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no studies in the literature that look at value assessment of cancer therapies from a benefit-
risk perspective.  Developing a MCDA model would help in assigning a value to these 
breast cancer therapies by quantifying the risks and the benefits and making the decision 
process more transparent and easier.  
SPECIFIC AIMS: 
1. To develop and validate predictive risk models to assess the risk of cardiovascular 
diseases (CVD) among cancer patients using machine learning algorithms 
a. To compare sociodemographic characteristics of cancer patients with CVD to 
those without CVD 
b. To build predictive risk models using random forest, gradient boosting and deep 
learning algorithms and compare the accuracy to standard regression models 
c. To validate the predictive risk models using cross validation techniques and 
evaluate the model fit on a varied sample 
d. To create an interactive web-based application using R-shiny to predict the risk 
of CVD among cancer patients using the most accurate model identified 
2. To assess cardiotoxicity associated with targeted therapies as compared to non-
targeted therapies and develop a model to conduct benefit-risk assessment of therapy 
regimens in breast cancer patients  
a. To describe the cancer therapy characteristics associated with the cardiotoxic 
adverse events in breast cancer patients receiving targeted therapies as 
compared to those receiving non-targeted therapies and evaluate the drug-
event association using a disproportionality analysis 
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b. To develop a Multi Criteria Decision Analysis (MCDA) model to conduct benefit-
risk assessment of breast cancer therapy regimens 
c. To conduct sensitivity analyses to assess the MCDA model performance and 
uncertainty in the model 
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CHAPTER 2: PREDICTIVE RISK MODELING FOR PREDICTION 
OF CVD RISK AMONG CANCER PATIENTS 
BACKGROUND: 
The increasing number of risk factors associated with CVD in cancer patients and 
the interactions within these have made it essential to build a predictive risk model which 
can incorporate all the predictors. Literature suggests that when the number of predictors 
is large along with interactions within these, the standard regression models are not 
accurate. A machine learning (ML) approach would build more accurate predictive 
models.1,2 A predictive risk model would help in guiding decision-making by presenting all 
the factors that put cancer patients at a higher risk of developing CVD. The growing 
availability of nationally representative datasets, together with advances in ML offer new 
opportunities for development of novel risk prediction models that are better at predicting 
risk. Such models have been shown to outperform standard statistical models particularly 
when the number of predictors is high and relationships more complex.3 A simple 
regression model predicts current risk based on the available data where as a predictive 
model built using a ML approach could predict the future risk based on the available data. 
A study conducted by Rahimian et al., looked at the prediction of risk models for ED visits 
using the ML approach and compared the model to the standard hazard models.2 The 
authors concluded that, ML approach produced more robust findings for a longer time 
horizon. Literature suggests that in general population, ML significantly improves the 
accuracy of cardiovascular risk prediction.4 Compared to the established risk prediction 
algorithm, ML algorithms such as random forest, gradient boosting and neural networks 
improved prediction. The superiority of ML has thus been established in predicting the risk 
of CVD in general population.4 However, none of the studies conducted so far have used 
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the ML approach to build a risk model for CVD amongst cancer patients. As stated earlier, 
cancer patients are at an even higher risk of developing CVD and the risk factors differ 
significantly than the general population. The predictive risk model would differ than that 
obtained in the general population. Developing a predictive risk model specifically in 
cancer patients would thus be beneficial in improving the accuracy of CVD risk prediction. 
It would eventually increase the number of patients identified who could benefit from 
preventive treatment and avoid unnecessary cardiac complications. The results from our 
study might also guide physicians in decision-making and building cardio-oncology 
guidelines. Characterizing the patients that have cancer and CVD diagnoses both and 
incorporating for interactions within the predictive model would help in tailoring CVD 
interventions by managing risk efficiently in cancer patients. Developing a dynamic web-
based application based on the most accurate ML algorithm that would predict the real 
time risk of CVD in cancer patients would also help the physicians planning the treatment 
regimen and prognosis of their cancer patients.   
Literature Review: 
The following search strategy using a combination of MeSH terms was 
used:  ((((((("Machine Learning"[MeSH] OR "Neural Networks (Computer)"[Mesh] OR 
"Algorithms"[Mesh:noexp]))) OR ("Machine learning" OR "Neural networks" OR "Neural 
network" OR "Network model" OR "Network models" OR "Deep learning" OR "Random 
Forest" OR "Gradient Boosting" OR "Algorithm" OR "Algorithms")))) AND ((("Angina" OR 
"Myocardial Infarction" OR "Coronary Artery Disease" OR "Congestive Heart Failure")) OR 
"Heart Diseases"[Mesh])) AND "Neoplasms"[Mesh]. The titles and abstracts were then 
screened for their eligibility using the following inclusion/exclusion criteria. 
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We included studies that looked at application of ML in predicting cardiovascular 
outcomes in cancer patients. We restricted our studies to those conducted in humans and 
published in English. We excluded studies that focused on cancer outcomes rather than 
cardiovascular outcomes or that did not look at CVD as a comorbidity. We also excluded 
studies that just looked at ML algorithms as a diagnostic/ imaging tool for malignant 
tumors. We excluded studies that looked at pediatric population or were narrative reviews 
not looking at any particular outcome.  
 The search strategy resulted into 228 studies. On applying the inclusion/exclusion 
criteria, 222 articles were excluded. The final literature review included six studies.5 – 10 
Figure 2 below includes a PRISMA flowchart of studies that were included in the literature 
review.  
 
 
 
 
 
 
 
 
 
Figure 2: PRISMA Flowchart of Literature Review (Aim 1) 
 
Total results through databases searching (n= 228) 
Abstracts reviewed for eligibility (n=30)  
Studies included (n= 6) 
Remove duplicates (n=11) 
Articles excluded (n=24): 
CVD not as a comorbidity 
(n=9) 
Use of ML for imaging and 
non-prediction tools (n=11) 
Reviews (n=4) 
 
Articles screened for eligibility (n=217) Article excluded (n=187) 
since they were not focused 
on machine learning 
algorithms or were not in 
cancer population 
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Table 2 below summarizes the studies that were included in the literature review. 
There were 6 studies that were summarized for the literature review to identify the gaps in 
the literature. Majority of these studies have looked at one specific type of cancer or have 
been diagnostic tools for cardiovascular outcomes in cancer patients. The number of 
studies looking at cardiovascular conditions in patients with cancer using ML algorithms 
has increased in the recent past due to the increasing popularity of the method.  
Table 2: Summary of Literature Review (Aim 1) 
 
There have been very few studies in the literature that have used ML algorithms to 
predict cardiovascular outcomes in cancer patients. Most of the studies that have used ML 
algorithms for prediction have been in general population. In cancer patients, the use of 
ML so far has been extensively as an imaging/ diagnostic tool to evaluate malignant 
Study Study Objective 
Gernaat et al., 20185 To apply a new deep learning algorithm for automated 
quantification of coronary artery calcifications among breast cancer 
patients 
Lessmann et al., 20186 To apply convolutional neural network method to automatically 
detect coronary artery, aorta and cardiac valve calcifications among 
lung cancer patients 
Hu et al., 20167 To develop a prediction model using a neural network to predict 
clinical deterioration (cardiac arrest) in adult hematologic malignant 
patients 
Takx et al., 20148 To determine the reliability of automated coronary artery 
calcification scoring in lung cancer screening population 
Dranitsaris et al., 20089 To develop a predictive model to estimate cardiotoxic risk for 
patients with breast cancer receiving anthracyclines 
Van Gerven et al., 200710 To predict the development of carcinoid heart disease in 
neuroendocrine malignant tumor patients using noisy-threshold 
classifier 
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tumors. However, there are 6 studies that have been summarized in table 2 that evaluated 
a ML tool to predict cardiovascular outcomes in cancer patients.  
There were two studies conducted by Gernaat et al. and Lessmann et al. that 
looked at automatic calcification scoring in cancer patients. Both these studies used a 
similar deep learning approach to quantify coronary artery calcifications (CAC) on 
radiotherapy computed tomography (CT) scans. The CT scans were evaluated to develop 
a deep learning algorithm using two convolutional neural networks. This algorithm was 
trained to automatically score the calcifications in the CT scans.5,6 The study conducted 
by Gernaat et al. focused on breast cancer patients, the algorithm was compared against 
manual scoring and it was concluded that the automatic scoring tool showed high 
reproducibility (proportion of agreement = 0.90, Intraclass correlation coefficient [ICC] = 
0.99) and was quicker than the conventional approaches to quantify calcifications.5 
Lessmann et al., looked at lung cancer patients and the algorithm enabled reliable 
automatic quantification of calcification (sensitivity = 92%) for lung cancer patients.6  
Hu et al. developed a prediction tool using a neural network model that would 
increase the predictive accuracy of detecting clinical deterioration (ICU transfer and 
cardiac arrest) among hospitalized patients with hematologic malignancies. EMR records 
of patients were used to build the model. The algorithm was trained on 565 (50%) 
hospitalized patients and cross-validation was performed on a separate 25% of the 
sample. Overall sensitivity of the neural network was found to be 84% whereas specificity 
was found to be 98%. The model correctly identified 7.6% of admissions to be clinically 
deteriorated whereas 92.4% did not result in clinical deterioration.7  
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Another study conducted by Takx et al. determined the agreement and reliability of 
such fully automated coronary artery calcium scoring in lung cancer screening population. 
There were 1749 CT scans that were analyzed to estimate the reliability as compared to 
manual scoring. Fully automated coronary calcium scoring in a lung cancer screening 
setting was found to be feasible with acceptable reliability and agreement (ICC = 0.90).8  
A study conducted by Dranitsaris et al. to develop a predictive model was the most 
relevant to our study aim. However, this study was restricted to breast cancer patients 
receiving anthracyclines and focused on treatment induced cardiotoxicity. A model was 
built based on generalized estimating equations logistic regression using the ML approach. 
This model was trained on breast cancer patients from a randomized controlled trial. The 
initial list of 20 predictors was reduced to six to be included in the final predictive model 
which estimated that prior anthracycline exposure was associated with a higher risk for 
cardiotoxicity on controlling for other factors.9  
Van Gerven at al. looked at predicting the development of carcinoid heart disease 
(CHD) among neuroendocrine tumor patients. There were 54 cases of patients enrolled 
from the Netherlands Cancer Institute that were analyzed to develop the model using 
noisy-threshold classifier as compared to naïve-Bayes classifier, logistic regression and 
decision-tree learning algorithm. The noisy-threshold classifier showed the best 
classification accuracy of 72% correctly classified cases.10 Other studies in the literature 
using ML algorithm have been on a noncancer population. 
Gaps in the literature: 
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 There is a lack of a predictive risk model which could incorporate all these risk 
factors in a single model and predict the future risk of CVD. As mentioned in the literature 
summary above, majority of these machine learning algorithms have been developed from 
a diagnostic perspective of quantifying a tumor or scoring these masses based on the CT 
scans. There are only two studies that looked at predicting clinical deterioration (cardiac 
arrest) or cardiotoxicity in cancer patients. These have however looked at a very small 
sample of a specific cancer type and have not incorporated appropriate algorithms that 
could handle interactions within predictors. These have also looked at a specific CVD 
outcome as opposed to the overall CVD risk in cancer patients. The aim of our study was 
thus to build a predictive risk model using machine learning algorithms that could 
incorporate a large number of predictors and interactions within these. This model would 
then be able to predict future CVD risk among cancer patients.  
Specific Aim 1: 
To develop and validate predictive risk models to assess the risk of cardiovascular 
diseases (CVD) among cancer patients using machine learning algorithms 
a. To compare the sociodemographic characteristics of cancer patients with CVD 
to those without CVD 
b. To build predictive risk models using random forest, gradient boosting and deep 
learning algorithms and compare the accuracy to standard regression models 
c. To validate the predictive risk models using cross validation techniques and 
evaluate the model fit on a varied sample 
d. To create an interactive web-based application using R-shiny to predict the risk 
of CVD among cancer patients using the most accurate model identified 
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CONCEPTUAL FRAMEWORK: 
 Our study aim 1 was based on the social determinants of health (SDOH) 
conceptual framework by the World Health Organization (WHO).11 This framework 
demonstrates how social, economic, and political factors influence a person’s 
socioeconomic position which, in turn, plays a role in determining health outcomes. 
Our study used these socioeconomic indicators along with certain cancer related 
and overall health related characteristics. We used age, gender, race, marital 
status, employment status, census region, income, education level, health 
insurance coverage and access to care characteristics as the socioeconomic 
determinants of health. Patient-related lifestyle factors, cancer related 
characteristics, overall related health factors, CVD screening services and 
medication adherence were the intermediary behavioral and biological 
determinants of health. We identified all the predictors that we used in the model 
based on literature evidence and social determinants of health conceptual 
framework. 
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METHODS AIM 1: TO DEVELOP AND VALIDATE PREDICTIVE RISK MODELS TO ASSESS THE RISK 
OF CARDIOVASCULAR DISEASES (CVD) AMONG CANCER PATIENTS USING THE MACHINE 
LEARNING ALGORITHMS 
Data Source:  
Medical Expenditure Panel Survey (MEPS) 2005-2015 files were used for the study. 
MEPS is a nationally representative survey that collects data on the health services that 
Americans use, frequency of utilization, costs and sources of payments associated with 
these, as well as data on the cost, scope, and breadth of health insurance held by and 
available to U.S. workers.12 The dataset was used to obtain complete information needed 
to identify risk of CVD amongst cancer patients and build a predictive risk model using 
machine-learning algorithms. The Full Year Consolidated, Medical Conditions, 
Prescription and Emergency/Inpatient/Outpatient/Office-based visits files from 2005-2015 
were used from MEPS to input data into the model. 
Proposed study design and sample:  
  Cross sectional study design was used for this study aim. The study sample 
consisted of patients diagnosed with cancer over the age of 18 years in the US from 2005-
2015.The Medical Conditions files of the Household Component were used to obtain the 
clinical classification codes to identify cancer patients. Clinical Classification Software 
(CCS) collapses categories based on ICD-9 codes and generates more meaningful codes 
which can be used to look at broader categories like ‘cancer’ and not a specific type of 
cancer. Hence, clinical classification codes of 11-44 were used to identify cancer patients. 
The study sample was then restricted to adult respondents who were diagnosed with or 
had cancer after the age of 18 years as identified by the CCS. Adults who died during the 
process of reporting were excluded. There were 48,829 patients identified with cancer 
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and complete information on their CVD status. Out of these, 4,612 patients were excluded 
since their CVD diagnosis was before their cancer diagnosis. Those with a chronic CVD 
diagnosis within 1 year of cancer diagnosis were also excluded since in this case it was 
possible that the CVD condition was unrelated to the cancer condition. The final study 
sample thus consisted of 44,217 cancer patients, out of which 12,339 (weighted 
percentage = 28.7%) patients had a chronic CVD diagnosis whereas 31,878 patients 
(weighted percentage = 71.3%) did not have CVD.  Majority of these patients with cancer 
and CVD had at least a 2 years’ time period between their cancer and CVD diagnoses 
extending up to 9-12 years.  Dates of diagnosis of cancer and CVD were used to estimate 
the mean time between cancer and CVD diagnoses. A categorical time variable was 
created to group patients into categories of time intervals between cancer and CVD such 
as 1-3 years, 3-5 years, 5-10years and > 10years. Table 3 summarizes the sample 
distribution based on the time interval between cancer and chronic CVD diagnoses 
among those who were diagnosed with cancer and CVD both. In addition to chronic CVD, 
there were 3,837 inpatient CVD procedures performed, 7,069 hospital stays due to CVD 
condition and 3,423 emergency visits due to CVD identified after the cancer diagnosis 
which were sub grouped as acute CVD events. These chronic and acute CVD events 
were analyzed separately.  
Table 3: Time Interval Between Cancer and Chronic CVD Diagnoses (N = 12,339) 
 
Time Interval Frequency N(%) 
2 - 3 years 3,265 (26.46) 
3 -5 years 1,384 (11.22) 
5 – 10 years 2,033 16.48) 
>10 years  3,916 (31.74) 
Missing 1,741 (14.1) 
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CVD diagnoses: 
 CVD diagnoses was identified using MIDX, ANGIDX, CHDDX AND OTHRDX from 
Full Year Consolidated files for myocardial infarction, angina, coronary heart disease and 
other heart diseases respectively for chronic CVD conditions. Acute CVD events were 
identified using the procedural or clinical classification codes from Inpatient, Outpatient 
and Emergency Room visits files. The dates of diagnoses of these were used to identify if 
the CVD was diagnosed before or after cancer and exclude those who had an acute CVD 
diagnosis before cancer. All these chronic and acute CVD events were analyzed at a 
patient level by transposing the diagnoses per patient. The predictive models were thus 
built to predict any one of the chronic/ acute event per patient. 
Other Study Variables: 
Full year consolidated files were used to identify patient demographics, lifestyle 
factors, access to care, cancer and overall health related characteristics and certain 
cardiovascular risk factors such as smoking, obesity, BMI, etc. Prescription medicines files 
were used to assess patient’s adherence to medications and the combinations of drugs 
that were prescribed. These medications were mainly cardio protective agents or 
preventative medications such as β-blockers, calcium channel blockers or statins that are 
prescribed to those with and without CVD both as a preventative measure. Medication 
adherence was calculated using a proportion of days covered (PDC) measure. A PDC is 
calculated by dividing the number of days in period covered by the total number of days in 
the period. We calculated the number of days in period covered by summing the total 
number of days supplied of medication and the number of refills in a particular year 
obtained from MEPS whereas the total number of days in period were 365 since we used 
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cross sectional files. We calculated separate PDCs for separate classes of drugs per 
patient and then calculated an average PDC per patient as a behavioral measure. 
Outpatient and Office-based visits files were used to assess if any visits were scheduled 
to discuss patient’s cardiovascular health. Discretization of some continuous variables like 
age and income was carried out to club them into meaningful categories, Table 4 below 
provides all the variables that were used to build the predictive risk model using the 
machine learning algorithms. 
Table 4: Study Variables for Aim 1b 
Variable Variable description 
Sociodemographic factors: 
-AGE05X – AGE15X*          
-SEX 
-RACEX 
-MARRY05X – MARRY15X* 
-EMPST31 
-REGION31 
-TTLP05X – TTLP15X*        
-EDUCYR 
-INSCOV05 – INSCOV15* 
-PRVEV05-15 (private insurance),   
MCREV05-15 (medicare), MCDEV05-15 
(medicaid), OPAEV05-15 (other public 
insurance)*  
 
 
 
-Age as of the most recent round 
-Gender 
-Racial background 
-Marital status 
-Employment status  
-Census region 
-Income level 
-Years of education received 
-Health insurance coverage indicator 
-Type of insurance coverage (these will 
be clubbed into a single variable with 
multiple categories, Tricare and 
Employer’s insurance would be coded 
as a separate ‘others’ category) 
Access to care: 
-MDUNAB42  
-PMUNAB42 
-HAVEUS42  
-DFTOUS42 
-LOCATN42 
 
-Unable to get necessary medical care 
-Unable to get necessary medications 
-Does the person have a USCa provider 
-Difficulty in getting to the USC provider 
-Where is the USC provider located 
Cancer and overall health related 
factors: 
-ADGENH42 
-ASTHDX, DIABDX, ARTHDX 
-CANCERT 
 
-CNCRREMS 
 
-Overall health status 
-Comorbidities (asthma, diabetes and 
arthritis respectively) 
-Type of cancer (using the binary cancer 
type indicator variables) 
-Remission stage 
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-CHEMOTH 
-RXNAME 
-TC1 classification 
-Radiotherapy, chemotherapy or surgery 
-Specific chemotherapy drug 
-Chemotherapy drug classification 
Patient-related lifestyle factors: 
-ADSMOK42 
-EXRCIS53 
-NOFAT53 
-BMINDX53 
 
-Do You currently smoke 
-Advised to exercise more 
-Restrict high fat/ cholesterol food 
-Adult BMI index 
CVD screening services and risk 
factors: 
-CHECK53 
-ADDRBP42 
-BPCHEK53 
-HIBPDX 
-CHOLCK53 
-CHOLDX 
 
 
-Time since last routine check up 
-Did the doctor check blood pressure 
-Time since last blood pressure check 
-High blood pressure diagnosis 
-Time since last cholesterol check up 
-High cholesterol diagnosis 
Medication adherence (To calculate 
PDC): 
-PURCHRD 
-RXBEGMM 
-RXDAYSUP 
 
-RXQUANTY 
-RXTOT05 – RXTOT15* 
 
 
-Round medication purchased in 
-Month person started taking medicine 
-Days supplied of the prescribed 
medicine 
-Number of tablets prescribed 
-Number of prescribed medicines 
including refills 
Complex survey measures: 
-PERWT05X-PERWT15X* 
-VARPSU 
-VARSTR 
 
-Weight variable for the person’s weight 
-Cluster variable 
-Strata variable 
*All of these variables would be recoded/ renamed appropriately to a common variable 
applicable to all the years 
a – Usual Source Care 
 
Statistical Analyses: 
 
Aim 1a: To compare the sociodemographic characteristics of cancer patients with 
CVD to those without CVD 
 The sociodemographic characteristics from table 2 were used to characterize the 
sample of patients with cancer and CVD both compared to those only with cancer. A 
binomial logistic regression was used to build this model to characterize the sample. 
Means and frequencies were used to summarize the descriptive statistics for continuous 
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and categorical variables respectively. SAS v9.4 was used for this aim. The logistic model 
built to characterize the sample also controlled for survey weights. The analyses thus 
conducted was weighted.  
Aim 1b: To build predictive risk models using random forest, gradient boosting and 
deep learning algorithms and compare the accuracy to standard regression models 
Models were trained using all the predictors mentioned in table 4, to predict CVD 
diagnoses after cancer. Missing values were imputed using multiple imputations 
techniques based on the missing data patterns. These models were built using different 
machine learning algorithms such as random forest (RF), gradient boosting and deep 
learning.12 The accuracy of these models in predicting the risk of CVD diagnoses was 
compared against each other and against standard regression technique. An 80:20 data 
split was used for the study where, 80% of random data was used to train the model 
whereas the remaining 20% of the sample was used for validation. The data was shuffled 
multiple times before making the split to ensure the randomness of observations. Before 
running any of the ML algorithms, the data was also centered and scaled as a standard 
data pre-processing practice. 
Random Forest (RF): RF analysis is based on an ensemble of classification trees. 
Literature also suggests that RF algorithms are the most highly applicable when it comes 
to predicting patients with high risks.13 It has also been suggested in the literature that 
tree-based algorithms such as RF, are able to handle missing values through the modeling 
process alleviating the need for imputation.14 This model was built using the R caret 
package. Gini impurity is the loss function that was used to evaluate the predictors that go 
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in the model to correctly classify patients as having CVD. Higher the gini coefficient, better 
the split and thus higher the accuracy. 13-15 
Gradient Boosting: Gradient boosting is a technique where in the models built in each 
iteration learn sequentially from the errors or false negatives (wrongly classified as having 
CVD) of the previous iteration and tends to minimize this error. R XGBOOST package was 
used to build gradient boosting models.15,16 Prior to building these models, the predictors 
to be used in the model were normalized or one hot encoded (created indicator variables 
for each category of the categorical variables) to fit the data preprocessing standards of a 
gradient boosting model.15,16 Variable importance plot (VIP) was used to evaluate the 
predictors that most significantly classify patients into getting diagnosed with CVD or not. 
Deep Learning: Deep learning along with accounting for the predictors individually also 
accounts for the interactions within these more accurately. All the predictors mentioned 
above formed the input layer of the model. Based on the model architecture specified, 
multiple hidden layers were built to interact these predictors and assign a weight which 
then predicted the risk of CVD diagnoses. Python KERAS package was used to build this 
model.17,18 The model architecture was defined by one input layer, two dense middle layers 
and an output layer. The activation function used was ‘sigmoid’. The models were 
compiled using stochastic gradient descent (SGD) as an optimizer, ‘binary crossentropy’ 
as a loss function and ‘accuracy’ as an evaluation metric with a learning rate of 0.01. The 
SGD optimizes the model to find the global loss minimum with the lowest cost function that 
can then predict the outcome with highest accuracy. The same model architecture was 
used to build acute and chronic CVD prediction models both. Batch normalization was also 
carried out by adding another batch normalization layer to the model which standardizes 
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the inputs to every layer and stabilizes the learning process.19,20 This layer was added for 
chronic and acute CVD prediction models both. 
 The prediction accuracies for the models were calculated using confusion matrix 
which determines the proportion of individuals correctly predicted by the model. The 
machine learning methods mentioned above, could not account for and were not 
compatible with sampling survey weights. The models built were thus unweighted. Adding 
the weight variables as general predictors into the model would not have been accurate 
since the weights by themselves should not predict the outcome in any way. They were 
still tested as predictors in the model, although this reduced the accuracy of the models.  
Standard regression techniques: A binomial logistic regression model was used which 
predicted the likelihood of getting diagnosed with a CVD based on all the predictors 
mentioned above. Interaction terms were tested for their significance too to be included in 
the model. Stepwise regression technique was used to assess the predictors to be 
included in the regression model. SAS v9.4 was used for regression. The regression model 
also controlled for complex survey methods. The person, strata and cluster weight 
variables as mentioned in Table 4 were the complex survey methods controlled for in the 
study. In addition to the standard regression model using stepwise regression technique, 
a GLMNET model was also built. GLMNET model is one of the intermediate models 
between standard regression technique and machine learning algorithms. GLMNET is a 
package that fits a generalized linear model via penalized maximum likelihood function. 
This penalty function is determined by the regularization path that is computed using all 
the variables involved in the model. The regularization pathway determines the alpha and 
the lambda values which are the tuning parameters. The regularization pathway obtained 
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determines these values for tuning parameters to maximize the likelihood function and 
thus improve accuracy of the model. 15,21 
Model performance and accuracy: 
 The remaining 20% of the data was used to test the model. The trained model by 
using different algorithms was used to make predictions for CVD diagnoses on the test 
sample. The number of true positives and false positives were calculated using the 
predicted and the observed sample. These class predictions and predicted probabilities 
were used to calculate the Receiver Operating Characteristic Area Under the Curve (ROC 
AUC) or a c-statistic using R and Python both. Higher the c-statistic, higher is the number 
of true positives and lower is the number of false negatives, thus making the model more 
accurate. A c-statistic was calculated for each of the models built to assess model 
performance. Sensitivity and specificity of these models were reported too. Categories of 
c-statistic as identified in the literature were used to interpret the results with respect to 
their accuracy. A c-statistic lower than 0.5 indicates a very poor model, 0.5-0.69 indicates 
a model  that is no better than predicting an outcome than random chance, 0.7-0.79 
indicates a good model, 0.8-0.99 indicates a strong model whereas a value of 1 means 
that the model perfectly predicts a certain outcome.22  
Handling missing data: 
 Missing data were imputed using the KNN-imputation method. This method imputes 
values for the missing variables using k-nearest neighbor averaging.23 In this method, an 
estimate for the missing value can be approximated by the values of the points that are 
closest to it, based on other variables. Variables that had about 10-25% missing values 
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were imputed using KNN imputations. Listwise deletion were used for other variables with 
very low proportion of random missing values (<5%). Some variables had more than 25% 
missing observations, for these variables another category was created within the variable 
to indicate that the value was missing.  
Aim 1c: To validate the predictive risk models using cross validation techniques 
and evaluate the model fit on a varied sample 
 The model was then validated using internal and external validation techniques.15 
For internal validation, the model was validated using a 10-fold cross validation technique 
on the entire sample. In order to further validate the model, the data was split based on 
the census regions of the population. Certain specific census regions were used to train 
the model whereas it was validated on the other census regions. Based on the prevalence 
of CVD across census regions, south and west regions were used to train the model 
whereas north and mid regions were used to test the model.24 We clubbed a region with 
high prevalence of CVD (south) with another with a relatively low prevalence (west) as a 
training sample to ensure uniformity and reduce bias. Similarly, for the testing sample we 
clubbed a high prevalence region (north) with a relatively low prevalence region (mid).24 
For external validation, the entire dataset from 2005-2015 was used to train the sample 
whereas the model was  tested on 2016-2017 dataset. Thus, chronological splitting was 
used for external validation of the model. This tested the robustness and generalizability 
of the model.  
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Aim 1d: To create an interactive web-based application using the R-shiny to predict 
the risk of CVD among cancer patients using the most accurate model identified 
 Using the most accurate machine learning/ regression model identified in aim 1b 
predicting the risk of CVD in cancer patients, an interactive web-based application was 
created which would dynamically predict probability of future CVD events in cancer 
patients. The application would be a user-friendly tool for the physicians to input patient 
and other characteristics of cancer patients to get an estimated probability of potential 
CVD risk in the future. The characteristics to be entered were based on the model results 
from aim1b and the variable importance plot which estimated the most important predictors 
of CVD risk in cancer patients. This web-based application was designed on R-shiny using 
the user interface (UI) and the server functions to define the shiny object (web 
application).25,26 The R built model predicting the risk of CVD most accurately was fed into 
the server function which then feeds into the user interface of the application to make 
predictions. Based on this model, the application predicts a probability of any future CVD 
event given the characteristics. 
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RESULTS: 
 The study sample consisted of 48,829 patients diagnosed with cancer in the United 
States (US) from 2005-2015. Of these, 16,951 (34.72%) patients also had a chronic CVD 
diagnosis whereas the remaining 31,878 (65.28%) patient had no chronic CVD diagnoses. 
Of the 16,951 patients, 4,612 patients had a CVD diagnosis before their cancer diagnosis 
and were thus excluded from the study. The final analyses were thus conducted on 12,339 
cancer patients with CVD (25.27%) as compared to 31,878 cancer patients without CVD 
(65.28%). There were fewer patients with CVD that reported their cancer type. Table 5 
below summarizes the distribution of patients with cancer and CVD both by their cancer 
type. Breast and prostate were the most frequent types of cancers among patients with 
CVD.  
Table 5: Patients With Cancer and CVD Both By Cancer Type In The US From 
2005-2015 
Table 6: Acute CVD Events In Patients With Cancer In The US From 2005-2015 
 
 
 
 
 
Cancer type Unweighted Frequency 
Prostate 1,824 
Breast 1,021 
Lung 834 
Colon 514 
Melanoma 417 
Cervix 103 
Pancreas 20 
Other 2,162 
CVD events in cancer patients Unweighted Frequency 
Hospital stay related to the condition 7,069 
Inpatient procedure 3,837 
Emergency room (ER) visits 3,423 
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Acute CVD events were also analyzed in our study. Table 6 above summarizes the 
number of acute CVD events that occurred in cancer patients post their cancer diagnoses. 
As observed from the table above, majority of acute CVD events were due to a hospital 
stay related to the CVD condition without any inpatient procedure or an ER visit required. 
These were the number of CVD events that occurred in cancer patients after their cancer 
diagnosis.  
Aim 1A: To compare the sociodemographic characteristics of cancer patients with 
CVD to those without CVD 
 Sociodemographic characteristics such as age, gender, race, marital status, 
education, employment status and income were compared across cancer patients with 
and without CVD. These results are summarized below in Table 7. 
Table 7: Sociodemographic Characteristics of Cancer Patients With And Without 
CVD In The US From 2005-2015 
Sociodemographic 
characteristis 
Cancer patients 
with CVD 
N(row%, column%) 
12,339(28.7) 
Cancer patients 
without CVD 
N(row%, column%) 
31,878(71.3) 
p-value 
Age, years (range) 
                         Mean 
 
71.2 
 
62.1 
 
<.0001* 
Age groups 
                18-44 years 
                45-65 years 
                   >65 years 
                       Missing 
 
302 (5.81, 2.0) 
3,791 (22.53, 26.3) 
7,501 (37.64, 66.6) 
745 (24.94, 5.1) 
 
4,211 (94.18, 13.2) 
11,922 (77.47, 36.4) 
13,590 (62.35, 44.4) 
2,155 (75.05, 6.1) 
 
 
<.0001* 
Gender 
                          Males 
                      Females 
                       Missing 
 
5876 (31.36, 47.0) 
6,463 (26.63, 53.0) 
0 (0) 
 
13,139 (68.63, 41.3) 
18,739 (73.37, 58.7) 
0 (0) 
 
 
0.2805 
Race 
Whites 
Blacks 
Asians 
 
9,437 (29.42, 89.8) 
2,376 (27.85, 8.12) 
449 (16.05, 1.6) 
 
24,504 (70.57, 86.6) 
5,207 (72.14, 8.5) 
1,518 (83.94, 3.3) 
 
 
0.1363 
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Multiple Races 
Missing 
77 (9.64, 0.4) 
0 (0) 
649 (90.35, 1.6) 
0 (0) 
Marital Status 
Married 
Widowed 
Divorced 
Separated 
Never Married 
Missing 
 
5,916 (26.5, 52.1) 
2,394 (41.59, 24) 
2,802 (29.03, 15.8) 
602 (71.11, 4.31) 
625 (12.06, 3.73) 
0 (0) 
 
17,518 (73.48, 58) 
4,684 (58.40, 13.6) 
4,535 (70.96, 15.5) 
427 (28.88, 0.7) 
4,266 (87.94, 11) 
448 (100, 1.2) 
 
 
 
<.0001* 
Education 
No education 
  Elementary/Middle School 
High School 
≤4 Years College 
5+ Years College 
Missing 
 
 
 
6 (3.75, 0.04) 
1,105 (30.60, 5.2) 
2,357 (21.83, 16.7) 
2,131 (22.82, 17.9) 
713 (25.25, 8.0) 
6,027 (36.21, 52) 
 
227 (96.24, 0.4) 
2,167 (69.39, 4.8) 
8,389 (78.16, 24.1) 
7,558 (77.17, 24.4) 
2,175 (74.74, 9.5) 
11,362 (63.78, 36.7) 
 
 
 
0.0479* 
 
Employment Status 
Employed 
Unemployed 
Missing 
 
2,555 (19.73, 23.8) 
9,780 (34.14, 76.1) 
4 (0.68, 0.03) 
 
11,259 (80.26, 39) 
19,931 (65.85, 59) 
688 (99.31, 2) 
 
 
<.0001* 
Income, per year 
Mean ($) 
 
34,117 
 
34,615 
 
0.3459 
Income groupsa 
Low 
Middle Class 
High 
Missing 
 
4,328 (24.38, 22) 
5,783 (31.63, 54.5) 
2,228 (27.18, 23.4) 
0 (0) 
 
10,887 (75.61, 27.4) 
14,865 (68.36, 47.4) 
6,126 (72.81, 25.2) 
0 (0) 
 
 
0.3041 
The frequencies reported are unweighted and percentages reported are weighted using the complex survey design  
*Significantly different characteristics across the two groups 
a – Low defined as income <100% FPL (<$12,060), middle class defined as income between the range of 100-400% FPL ($12,060 
- $48,240) and high defined as income over 400% FPL (>$48,240) 
 
 
 As seen from the table above, age, marital status, education and employment 
status differed significantly across cancer patients with and without CVD on conducting 
bivariate analyses. Cancer patients with CVD were older (mean age: 71.2years vs 
62.1years), had lower proportion of those married (52.1% vs 58%) and higher proportion 
of unemployed (76.1% vs 59%). These factors were included in a logistic model to 
calculate adjusted odds ratios. Results from the adjusted logistic regression are 
summarized in table 8 below. Odds ratios (OR) adjusted for all the sociodemographic 
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factors are reported in table 8. The probability modeled was getting diagnosed with CVD. 
In presence of all the other variables, age, race, marital status, education and employment 
status had significant OR associated with these. The significance of these variables was 
estimated based on the overall p-value as observed from the type 3 effect. However, on 
assessing the confidence intervals associated with these  odds ratio estimates it was 
observed that the significance could be because of a wide range of interval associated 
with some categories. This could have been a result of low sample size for those particular 
categories as compared to the sample size of the ‘Reference’ category. This suggests that 
the significance of certain variables such as race, marital status and education could have 
been attributable to low sample size for significant goups (Race- Multiple races, Marital 
Status – Separated and Education – No education) withing these variables. The odds ratio 
estimates suggested that as compared to those who were >65years, those who were 
younger were less likely to be diagnosed with CVD.  As compared to whites, all the other 
races were less likely to be diagnosed with CVD. As compared to those who were married, 
those who were widowed, divorced or separated were more likely whereas those never 
married were less likely to be diagnosed with CVD. As compared to those who had ≤4 
years college,  those who had no education or studied till highschool were less likely where 
as those who studied till elementary/middle school and 5+ years college were more likely 
to get diagnosed with CVD. Those employed were less likely to be diagnosed with CVD 
as compared to those who were unemployed. 
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Table 8: Survey logistic Results for the Likelihood of Being Diagnosed With CVD 
Along with Cancer Based on the Sociodemographic Characteristics Associated 
With Cancer Patients In the US From 2005-2015 
 
Odds Ratio Estimates 
Effect Point Estimate 95% Wald Confidence Limits 
Age* 
18-44 years  0.169 0.086 0.331 
45-65 years  0.643 0.394 1.047 
>65 years Reference Reference Reference 
Gender 
Males 1.262 0.804 1.980 
Females Reference Reference Reference 
Race* 
Blacks 0.984 0.498 1.945 
Asians 0.594 0.247 1.432 
Multiple Races 0.222 0.067 0.730 
Whites Reference Reference Reference 
Marital Status* 
Widowed 1.559 0.850 2.764 
Divorced 1.073 0.564 2.047 
Separated 13.017 3.527 48.049 
Never Married 0.712 0.335 1.505 
Married Reference Reference Reference 
Education* 
No education 0.100 0.011 0.877 
Elementary/ Middle School  1.215 0.359 4.106 
Highschool 0.997 0.489 2.032 
5+ Years College  1.239 0.504 3.045 
≤4 Years College Reference Reference Reference 
Employment Status* 
Employed 0.568 0.349 0.924 
44 
 
Unemployed Reference Reference Reference 
Income level 
Low  0.774 0.493 1.215 
High 1.268 0.754 2.132 
Middle class Reference Reference Reference 
*Significantly associated characteristics with the likelihood of being diagnosed with CVD alongwith cancer 
The probability modeled above is cancer patients being diagnosed with CVD 
 
 
Aim 1B: To build predictive risk models using random forest, gradient boosting and 
deep learning algorithms and compare the accuracy to standard regression models 
 In order to build the predictive risk model, the entire dataset was split into training 
and test validation splits. The baseline characteristics of training and test datasets are 
summarized below in table 9. This table also shows the proportion of missing values within 
each predictor. For the categorical predictors that had less than 5% missing data, listwise 
deletion was used to perform further analyses on complete cases. Those that had more 
than 10% but less than 25% missing data were imputed using KNN imputation method. 
This KNN imputation method used 6 nearby neighbors to impute the missing observation 
with a mean of 6 nearby neighbors. Those categorical variables that had more than 25% 
missing data used another level of category to indicate that data was missing. The missing 
continuous variables with less than 10% missing were imputed using the mean imputation 
technique by assigning the overall mean value of the variable to the missing observation.  
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Table 9: Baseline Characteristics of Training and Test Data Splits Used For 
Prediction 
Characteristic Training dataset 
N (%) 
35,858 (80) 
Test dataset 
N (%) 
8,964 (20) 
Sociodemographic factors  
Age groups 
                18-44 years 
                45-65 years 
                   >65 years 
                                   Missing 
 
 
3,733 (10.4) 
12,726 (35.5) 
16,986 (47.4) 
2,413 (6.7) 
 
916 (10.2) 
3,194 (35.6) 
4,289 (47.8) 
565 (6.3) 
Gender 
                          Males 
                      Females 
                                   Missing 
 
 
15,398 (43) 
20,460 (57) 
0 (0) 
 
3,905 (43.6) 
5,059 (56.4) 
0 (0) 
Race 
Whites 
Blacks 
Asians 
Multiple Races 
Missing 
 
 
27,536 (76.8) 
6,147 (17.1) 
1,548 (4.3) 
627 (1.7) 
0 (0) 
 
6,829 (76.2) 
1,551 (17.3) 
425 (4.7) 
159 (1.8) 
0 (0) 
Marital status 
Married 
Widowed 
Divorced 
Separated 
Never Married 
Missing 
 
 
18,879 (52.6) 
5,722 (15.9) 
5,962 (16.6) 
831 (2.3) 
4,061 (11.3) 
403 (1.1) 
 
4,718 (52.6) 
1,468 (16.4) 
1,505 (16.8) 
203 (2.2) 
981 (10.9) 
89 (0.9) 
Education 
No education 
Elementary/Middle School 
High School 
≤4 Years College 
5+ Years College 
Missing 
 
 
197 (0.5) 
2,652 (7.4) 
8,750 (24.4) 
7,732 (21.5) 
2,368 (6.6) 
14,159 (39.4) 
 
36 (0.4) 
673 (7.5) 
2,206 (24.6) 
1,990 (22.2) 
563 (6.3) 
3,496 (39) 
Employment status 
Employed 
Unemployed 
Missing 
 
 
 
11,163 (31.1) 
24,052 (67.1) 
643 (1.8) 
 
2,792 (31.1) 
6,019 (67.1) 
153 (1.7) 
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Income groupsa 
Low 
Middle Class 
High 
Missing 
 
 
12,520 (34.9) 
16,689 (46.5) 
6,649 (18.5) 
0 (0) 
 
3,105 (34.6) 
4,108 (45.8) 
1,751 (19.5) 
0 (0) 
Census region 
Northeast 
Midwest 
South 
West 
Missing 
 
 
5,982 (16.7) 
7,792 (21.7) 
14,482 (40.4) 
7,509 (20.9) 
93 (0.2) 
 
1,460 (16.3) 
1,947 (21.7) 
3,666 (40.9) 
1,873 (20.9) 
18 (0.2) 
Health insurance coverage 
Any private 
Public only 
Uninsured 
Missing 
 
 
19,185 (53.5) 
15,091 (42.1) 
1,582 (4.4) 
0 (0) 
 
4,929 (55) 
3,642 (40.6) 
393 (4.3) 
0 (0) 
Type of insurance coverage* 
Private insurance 
Medicare 
Medicaid 
Other public insurance 
Missing 
 
17,907 (49.9) 
21,299 (59.1) 
8,144 (22.7) 
67 (0.2) 
0 (0) 
 
4,577 (51.1) 
5,349 (59.7) 
1,960 (21.9) 
16 (0.2) 
0 (0) 
Access to care 
Unable to get necessary medical care 
Yes 
No 
Missing 
 
 
1,036 (2.9) 
32,604  (90.9) 
2,218 (6.2) 
 
253 (2.8) 
8,187 (91.3) 
524 (5.8) 
Unable to get necessary medications 
Yes 
No 
Missing 
 
 
1,581 (4.4) 
32,089 (89.5) 
2,188 (6.1) 
 
399 (4.5) 
8,040 (89.7) 
525 (5.9) 
Person has a USCb provider 
Yes 
No 
Missing 
 
 
31,525 (87.9) 
2005 (5.6) 
2,328 (6.5) 
 
7,900 (88.1) 
507 (5.7) 
557 (6.2) 
Difficulty to get to the USC provider 
Very difficult 
Somewhat difficult 
Not too difficult 
Not at all difficult 
 
294 (0.8) 
1,982 (5.5) 
4,260 (11.9) 
13,158 (36.7) 
 
66 (0.7) 
479 (5.3) 
1,081 (12.1) 
3,365 (37.5) 
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Missing 16,164 (45.1) 3,973 (44.3) 
Location of the USC provider 
Office 
Hospital, not ER 
Hospital, ER 
Missing 
 
 
24,464 (68.2) 
6,920 (19.3) 
44 (0.12) 
4,430 (12.4) 
 
6,141 (68.5) 
1,726 (19.3) 
11 (0.1) 
1,086 (12.1) 
Cancer and overall health related factors 
Overall health status 
Excellent 
Very good 
Good 
Fair 
Poor 
Missing 
 
 
2,093 (5.8) 
6,385 (17.9) 
10,593 (29.5) 
8,569 (23.9) 
3,134 (8.7) 
5,084 (14.2) 
 
493 (5.5) 
1,687 (18.8) 
2,649 (29.6) 
2,149 (24) 
757 (8.4) 
1,229 (13.7) 
Comorbidities* 
Asthma 
Diabetes 
Arthritis 
Missing 
 
 
3,835 (10.7) 
7,035 (19.6) 
15,703 (43.8) 
7,175 (20.01) 
 
932 (10.4) 
1,826 (20.4) 
4,004 (44.7) 
1,900 (21.2) 
Cancer type 
Breast 
Lung 
Cervix 
Prostate 
Pancreas 
Colon 
Melanoma 
Other 
Missing 
 
 
2,601 (7.2) 
939 (2.6) 
305 (0.8) 
2,448 (6.8) 
7 (0.02) 
905 (2.5) 
734 (2.1) 
3,719 (10.4) 
18,630 (51.9) 
 
628 (7) 
234 (2.6) 
71 (0.7) 
582 (6.4) 
2 (0.02) 
211 (2.4) 
193 (2.1) 
916 (10.2) 
4,657 (51.9) 
Cancer treatment received*┼ 
Radiotherapy 
Chemotherapy 
Surgery 
Missing 
 
 
429 (1.2) 
708 (2) 
2,960 (8.2) 
31,761 (88.5) 
 
99 (1.1) 
173 (1.9) 
673 (7.5) 
8,019 (89.4) 
Cancer in remission 
Yes 
No 
Missing 
 
 
2,546 (7.1) 
430 (1.2) 
32,882 (91.7) 
 
627 (7.0) 
99 (1.1) 
8,238 (91.9) 
Medication adherence 
PDC (>80%) 
 
17,136 (47.79) 
 
4,265 (47.57) 
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PDC (<80%) 
Missing 
 
6,942 (19.36) 
11,780 (32.85) 
1,766 (19.70) 
2,933 (32.73) 
Patient-related lifestyle factors 
Current smoking status 
Smoker 
Nonsmoker 
Missing 
 
 
4,031 (11.2) 
26,914 (75.1) 
4,913 (13.6) 
 
1,024 (11.4) 
6,746 (75.3) 
1,194 (13.3) 
Advised to exercise more 
Yes 
No  
Missing 
 
15,997 (44.6) 
15,241 (42.5) 
4,620 (12.8) 
 
4,015 (44.8) 
3,829 (42.7) 
1,120 (12.5) 
Advised to restrict high fat/ cholesterol 
food 
Yes  
No  
Missing 
 
 
16,030 (44.7) 
15,585 (43.46) 
4,243 (11.8) 
 
4,024 (44.9) 
3,887 (43.4) 
1,053 (11.7) 
Adult BMI indexc 
Underweight (< 18.5 kg/m2) 
Normal weight (18.5 – 24.9 kg/m2) 
Overweight (25 – 29.9 kg/m2) 
Obese ( >30 kg/m2) 
Missing 
 
 
5,338 (14.8) 
10,070 (28.1) 
11,002 (30.6) 
8,949 (24.9) 
499 (1.4) 
 
1,300 (14.5) 
2,506 (27.9) 
2,813 (31.4) 
2,228 (24.8) 
117 (1.3) 
CVD screening factors and risk factors 
Time since last routine check up 
< 1 year 
1-3 years 
4-5 years 
>5 years 
Never 
Missing 
 
 
26,954 (75.2) 
2,554 (7.1) 
414 (1.2) 
727 (2) 
572 (1.6) 
4,637 (12.9) 
 
6,721 (75) 
652 (7.3) 
107 (1.2) 
199 (2.2) 
152 (1.7) 
1,133 (12.6) 
Blood pressure checked by doctor 
Yes 
No 
Missing 
 
 
29,724 (82.9) 
765 (2.1) 
5,369 (15) 
 
7,445 (83.1) 
204 (2.3) 
1,315 (14.7) 
Time since last blood pressure check 
< 1 year 
1-3 years 
4-5 years 
>5 years 
Never 
 
31,149 (86.9) 
664 (1.9) 
16 (0.04) 
91 (0.3) 
21 (0.05) 
 
7,818 (87.2) 
167 (1.9) 
3 (0.03) 
18 (0.2) 
4 (0.04) 
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Missing 
 
3,917 (10.9) 954 (10.6) 
High blood pressure diagnosis 
Yes 
No  
Missing 
 
 
19,520 (54.4) 
8,751 (24.4) 
7,587 (21.2) 
 
4,936 (55.1) 
2,217 (24.7) 
1,811 (20.2) 
Time since last cholesterol check 
< 1 year 
1-3 years 
4-5 years 
>5 years 
Never 
Missing 
 
 
 
27,460 (76.6) 
2,307 (6.4) 
200 (0.6) 
592 (1.6) 
708 (1.9) 
4,591 (12.8) 
 
6,873 (76.7) 
575 (6.4) 
50 (0.6) 
159 (1.8) 
185 (2.1) 
1,122 (12.5) 
High cholesterol diagnosis 
Yes 
No 
Missing 
 
 
 
17,192 (47.9) 
11,068 (30.9) 
7,598 (21.2) 
 
4,390 (49) 
2,759 (30.8) 
1,815 (20.2) 
CVD outcome 
CVD diagnosis (Chronic) 
Yes  
No 
 
9,908 (27.6) 
25,950 (72.4) 
 
2,518 (28.1) 
6,446 (71.9) 
CVD (Acute) 
Yes 
No 
 
 
7,949 (22.17) 
27,909 (77.83) 
 
2,097 (23.4) 
6,867 (76.6) 
The frequencies and percentages reported are unweighted 
*People could have more than one of the listed alternatives 
┼ Specific cancer therapy for those available was also controlled 
¥ Medication adherence calculated using PDC (>80% - adherent, <80% - adherent) from round/ month 
medication obtained in, days suppleid of medication and number of refills  
a – Low defined as income <100% FPL (<$12,060), middle class defined as income between the range of 
100-400% FPL ($12,060 - $48,240) and high defined as income over 400% FPL (>$48,240) 
b – Usual Source Care 
c – BMI ranges obtained from the American Cancer Society definitions 
 
 On imputing the missing data using KNN imputation and using listwise deletion to 
retain the complete cases, the training and test datasets were centered and scaled as a 
part of data pre-processing that is required for machine learning algorithm. Once the data 
was ready, it was used to build conventional regression, random forest, gradient boosting 
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and deep learning models. These models were built to predict the risk of an acute 
cardiovascular condition among patients with cancer. Similar models were built to predict 
the risk of chronic CVD as well. 
Regression model: 
 Figure 3 below depicts the ROC curve obtained using a conventional regression 
model to predict the risk of an acute CVD event using all the predictors mentioned in table 
9 above. As observed from the ROC curve, the c-statistic obtained was 0.7534. A c-
statistic in the range of 0.7 – 0.79 indicates a good model. This shows that the model built 
using standard regression was good in making predictions. A similar model was built for 
predicting chronic CVD events using the same predictors. The regression model for 
chronic CVD events generated a c-statistic of 0.7641 which was slightly higher than that 
for acute CVD events. The ROC obtained on building this model is summarized in figure 
4 below. This suggests that the conventional regression model built for predicting chronic 
CVD events was more accurate than that built for acute CVD events. A c-statistic of 0.7641 
indicates a good model in predicting the risk of chronic CVD in cancer patients. 
 
Figure 3: ROC  for Acute CVD  Prediction Using a Regression Model 
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Figure 4: ROC  for Chronic CVD  Prediction Using a Regression Model 
 
      GLMNET package was used to build the GLMNET model. The regularization paths 
obtained for the acute and chronic CVD models are summarized in appendix figures 1 and 
2. The regularization paths suggested the use of ridge regression for acute and chronic 
CVD models both with α=0  as the penalty function. The c-statistic obtained by conducting 
ridge regression for acute and chronic CVD was 0.7853 (Sensitivity = 0.9846) and 0.7349 
(Sensitivity = 0.9473) respectively. Thus, it was observed that for acute CVD, the GLMNET 
(ridge regression) model performed better than the conventional regression model, 
whereas for chronic CVD prediction model the traditional regression model performed 
better than the GLMNET model. 
Random forest model: 
 Random forest model was built using all the predictors mentioned in table 9 above 
to predict the risk of an acute CVD event. The model was built using 5 cross validation 
sets which use five bootstraps of samples on the same set of variables. On trying different 
number and combinations of predictors to predict the outcome by building different trees, 
a model with 9 variables was chosen as the best model. This model with 9 variables would 
predict the risk of acute CVD event most accurately and with the lowest validation error. 
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Figure 5 below depicts the learning curves of a random forest model built to predict acute 
CVD event. It can be seen from the figure that the model has the highest cross validation 
accuracy and highest gini gain when the number of predictors are 9 after which the model 
does not improve much. The accuracies based on the gini gains with each set of predictor 
combination are summarized in table 10 below. 
 
Figure 5: Learning Curves for a Random Forest Model Predicting an Acute CVD  Event 
Table 10: Learning Accuracies for Random Forest Model Predicting an Acute CVD 
Event 
 
 
  
                 Similar model results were obtained for building predictive models for chronic 
CVD events. In this case, the most accurate model in predicting the risk of chronic CVD 
events in cancer patients was the one with 7 predictors. The learning curves obtained on 
training the random forest model are as observed in figure  6 below. 
Number of predictors Accuracy 
2 0.9641 
9 0.9754 
16 0.9741 
53 
 
 
Figure 6: Learning Curves for a Random Forest Model Predicting Chronic CVD 
 
 It can be seen from the figure that the model had the highest cross validation 
accuracy and highest gini gain when the number of predictors are 7 over which the model 
does not improve much. The accuracies based on the gini gains with each set of predictor 
combination are summarized in table 11 below. The model with 7 predictors had the 
highest accuracy. 
Table 11: Learning Accuracies for Random Forest Model Predicting Chronic CVD 
 
 
 
               The model results from the random forest models built for chronic and acute CVD 
prediction in cancer patients were used to build the variable importance values. These 
values assign a relative importance value starting with 100 for the most important variable 
and ranking the variables in a descending order. Following table 12 and table 13 
Number of predictors Accuracy 
2 0.9414 
7 0.9888 
12 0.9874 
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summarizes the variable importance values for the most important predictors identified 
using the random forest model for chronic and acute CVD events respectively. 
Table 12: Variable Important Values for the Random Forest Model Built for 
Predicting Chronic CVD 
Predictor Overall value 
Medication adherence 100 
Cholesterol diagnosis 98.20 
High blood pressure diagnosis 77.39 
Diabetes diagnosis 69.03 
Arthritis diagnosis 68.89 
Overall health 59.52 
Difficulty to get to the provider 45.23 
Census region 41.55 
Income 36.71 
Marital status 35.86 
 Table 13: Variable Important Values for the Random Forest Model Built for 
Predicting Acute CVD Events 
Predictor Overall value 
Overall health 100 
Medication adherence 80.96 
Marital status 63.10 
Census region 62.47 
Income 47.93 
Provider location 44.26 
Gender 41.75 
Difficulty to get to the provider 40.51 
Unable to get necessary prescribed medicines 38.20 
Cholesterol diagnosis 36.87 
 
Gradient Boosting model: 
 Before building a gradient boosting model, the data matrix was converted using one 
hot encoding into a matrix with just binary responses by flagging each indicator. A gradient 
boosting model was trained using 100 iterations with the validation error reducing with 
every iteration. The evaluation metric used for the model was ‘error’. The same modeling 
techniques were used to build predictive models for acute as well as chronic CVD events. 
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Every 10 rounds of iteration were printed and are summarized in table 14 below for acute 
CVD events and table 15 for chronic CVD events. For acute CVD events and chronic CVD, 
tables 14 and 15 show that the train and the test error reduce with every iteration with 
iteration 91 being the point where the models are at their best since the error does not 
change much beyond that point. The final validation error for acute CVD prediction model 
obtained was 0.1087 and that obtained for chronic CVD prediction model was 0.1483. The 
ROC obtained for acute CVD prediction model is as seen in figure 7 below with a c-statistic 
of 0.7833 and that obtained for chronic CVD is as observed in figure 8 below with a c-
statistic of 0.7608. The gradient boosting model was thus less accurate in predicting 
chronic CVD as compared to acute CVD event.  
Table 14: Errors Associated With Each Iteration of Gradient Boosting Algorithm 
For Predicting Acute CVD Event 
Iteration Train error Test error 
1 0.1576 0.1589 
11 0.1303 0.1325 
21 0.1229 0.1255 
31 0.1169 0.1200 
41 0.1143 0.1173 
51 0.1112 0.1149 
61 0.1092 0.1136 
71 0.1065 0.1111 
81 0.1054 0.1101 
91 0.1039 0.1092 
100 0.1032 0.1087 
 
Table 15: Errors Associated With Each Iteration of Gradient Boosting Algorithm 
For Predicting Chronic CVD Event 
Iteration Train error Test error 
1 0.2149 0.2160 
11 0.1831 0.1850 
21 0.1677 0.1698 
31 0.1600 0.1630 
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41 0.1570 0.1607 
51 0.1522 0.1563 
61 0.1486 0.1528 
71 0.1469 0.1512 
81 0.1451 0.1502 
91 0.1433 0.1484 
100 0.1427 0.1483 
 
 
Figure 7: ROC Obtained with a Gradient Boosting Model for Acute CVD Event 
 
 
Figure 8: ROC Obtained with a Gradient Boosting Model for Chronic CVD 
 
 The  model results were also used to plot a variable importance plot (VIP) to 
evaluate the predictors that have the most significant effect on predicting the acute CVD 
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outcome. The  VIP is depicted in figure 9 below which suggests that medication adherence 
(identified from the number of refills), overall health, BMI, marital status and education 
were identified as the top 5 predictors of an acute CVD event. 
 
Figure 9: Variable Importance Plot Based on The Gradient Boosting Model for Acute CVD 
Events 
                     
             Similar VIP was also used to identify the most important predictors responsible in 
predicting a chronic CVD outcome among cancer patients. Figure 10 below summarizes 
the most important predictors which have identified medication adherence (identified using 
Medication Adherence 
Overall Health 
Unable to get necessary medications 
Body Mass Index (BMI) 
Census Region 
Marital Status 
Difficulty getting to the provider 
Education 
Income 
Blood Pressure Diagnosis 
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the number of refills), cholesterol, arthritis, blood pressure diagnosis and overall health to 
be the most important in predicting the risk of chronic CVD in cancer patients.  
 
Figure 10: Variable Importance Plot Based on The Gradient Boosting Model for Chronic 
CVD Events 
 
 On comparing the most important predictors that were suggested by using the 
gradient boosting model (figure 9) to the most important predictors suggested by the 
random forest model (table 13) in predicting acute CVD event, most of the significant 
predictors identified were the same. Both the algorithms thus, predicted similar factors to 
be the most significant in predicting the risk of acute CVD events in cancer patients. Other 
than the predictors that were the same in both the algorithms, random forest model 
Medication Adherence 
Cholesterol Diagnosis 
Arthritis Diagnosis 
Blood Pressure Diagnosis 
Overall Health 
Marital Status 
Education 
Race 
Census Region 
Difficulty getting to the provider 
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suggested provider’s location, gender and cholesterol diagnosis instead of BMI, education 
and high blood pressure diagnosis in the gradient boosting model for predicting acute CVD 
events among cancer patients. Similar results were obtained for the chronic CVD 
prediction model with both the algorithms (figure 10 and table 12) predicting similar factors 
to be the most significant in predicting chronic CVD risk in cancer patients. In addition to 
the predictors that were the same in both the algorithms, random forest model predicted 
diabetes diagnosis and income instead of education and race in the gradient boosting 
model in predicting chronic CVD in cancer patients.  
Deep learning model: 
 Deep learning models were trained using 50 epochs and a batch size of 16 to build 
predictive models to predict the risk of acute CVD events and chronic CVD in cancer 
patients. Two separate models each predicting an acute CVD event and chronic CVD 
respectively were built using the same architecture. The models were then fit on the 
training and test samples to obtain learning curves as depicted in figure 11 and 12 below 
for acute CVD and chronic CVD events respectively. The learning curves obtained after 
conducting batch normalization for acute and chronic CVD prediction models are depicted 
in appendix figures 3 and 4 respectively. For an acute CVD event prediction model, the 
model accuracy was the highest with around 30 epochs with the highest accuracy of 
around 0.83. The c-statistic obtained for this model was 0.8267 which was higher 
compared to a standard regression, GLM net and gradient boosting models for acute CVD 
event prediction model. For a chronic CVD prediction model, the model accuracy was the 
highest with 10 epochs with the highest accuracy of around 0.77. The c-statistic obtained 
for this model was 0.7662 which was higher compared to standard regression, GLM net 
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models and slightly higher than the gradient boosting model for chronic CVD prediction 
model.  
 
Figure 11: Learning Curves for the Deep Learning Acute CVD Prediction Model 
 
Figure 12: Learning Curves for the Deep Learning Chronic CVD Prediction Model 
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Comparison of all the predictive risk models: 
 A comparison of all the models built to predict the risk of an acute CVD event has 
been summarized below in Table 16. This table shows that a standard regression model 
had the lowest predictive power with a c-statistic of 0.7534 whereas a random forest model 
had the highest predictive power with a  c-statistic of 0.9738 followed by a deep learning 
model. The gradient boosting and GLM net models had almost the same predictive power. 
This suggests that with a large number of predictors the machine learning algorithms 
perform better than the conventional regression technique. 
Table 16: Comparison of Acute CVD Prediction Models 
 
 
 
 A comparison of all the models built to predict the risk of chronic CVD has been 
summarized below in Table 17. This table shows that a GLMNet model had the lowest 
predictive power with a c-statistic of around 0.73  whereas a random forest model had the 
highest predictive power with a  c-statistic of 0.9872. Standard regression, gradient 
boosting and deep learning models had a c-statistic of around 0.76. This suggests that the 
conventional regression model in this case performed as well as some of the machine 
learning algorithms such as gradient boosting and deep learning in making predictions. 
Random forest model was the most accurate in making predictions in acute and chronic 
CVD conditions both.  
Model c-statistic 
Standard regression 0.7534 
GLM net 0.7853 
Random Forest 0.9738 
Gradient Boosting 0.7833 
Deep Learning 0.8267 
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Table 17: Comparison of Chronic CVD Prediction Models 
 
 
 
 
Aim 1c: To validate the predictive risk models using cross validation techniques 
and evaluating the model fit on a varied sample 
 As random forest model was the one identified to be the most accurate on 
comparison with other models for chronic as well as acute CVD risk prediction, it was 
further validated. The chronic and acute CVD event models were validated internally and 
externally using 10-fold cross validation techniques. For internal validation, the data for 
both the models was split based on the census regions. South and west regions were used 
to train the models whereas north and mid regions were used to test the model. These 
regions were split based on the prevalence of CVD in these regions so they can be 
compared without any bias involved. A sample of 27,530 records identified in the south 
and the west regions were used to train the models whereas a sample of 17,181 records 
in the north and the mid regions were used to test the model. On training the acute CVD 
events model using south and west regions, following learning curve in figure 13 was 
observed where a model with 7 predictors like the one obtained above was identified as 
the best model. This model was then tested on north and mid regions to generate the 
following accuracy metrics reported in table 18.  
Model c-statistic 
Standard regression 0.7641 
GLM net 0.7349 
Random Forest 0.9872 
Gradient Boosting 0.7608 
Deep Learning 0.7662 
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Figure 13: Learning Curves for Internal Validation of Random Forest Model using South 
and West Census Regions for Acute CVD Events Prediction 
 
 
Table 18: Accuracy Metrics for Internal Validation of Acute CVD Events Prediction 
Model 
 
 
   
A c-statistic of 0.6808 suggests that the model trained using certain census regions 
does not perform extremely well on other census regions. This could be due to the innate 
differences in the demographics of these regions, food patterns etc. However, the 
accuracy rate as high as 77.15% and the c-statistic close to 0.7, suggests that the model 
outcomes are not completely random. 
Similarly, for chronic CVD prediction model, the following learning curves as 
obtained in figure 14 were obtained on training the model on south and west regions. A 
Metric Value 
c-statistic 0.6808 
Accuracy 0.7715 
Sensitivity 0.8597 
Specificity 0.4850 
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model with 7 predictors was identified as the best model. This model was then tested on 
north and mid regions to generate the following accuracy metrics reported in table 19.  
 
Figure 14: Learning Curves for Internal Validation of Random Forest Model using South 
and West Census Regions for Chronic CVD Prediction 
Table 19: Accuracy Metrics for Internal Validation of Chronic CVD Events 
Prediction Model 
 
 
 
A c-statistic of 0.5488 suggests that the model trained using certain census regions 
does not perform well on other census regions. Thus on internal validation it was observed 
that the c-statistic obtained with acute and chronic CVD models both was low. The chronic 
CVD prediction model was further less accurate than the one built for predicting acute 
CVD events. This could be due to the innate differences in the demographics of these 
regions, food patterns etc. that could not be completely controlled for in our model due to 
data limitations. Medical practice patterns across regions also differ which could also lead 
Metric Value 
c-statistic 0.5488 
Accuracy 0.6585 
Sensitivity 0.8235 
Specificity 0.2742 
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to increased screening and thus increased diagnosis in certain regions due to increased 
access.27,28 This suggests that if data was available accounting for some of these factors 
in our predictive models, it could increase the generalizability and validity of the model. 
The accuracy rate was also 0.6585, which was lower than that obtained for acute CVD 
events and suggested that the outcome was predicted accurately 65% of the time based 
on the current data. 
For external validation, the originally trained chronic and acute CVD prediction 
models using 2005-2015 training dataset were used to test on 2016-2017 data. These 
originally trained models were then used to predict the risk of acute and chronic CVD 
events for a sample of 21,674 events observed in 2016-2017. On performing the 
validation on 2016-2017 following test metrics were obtained as mentioned in table 20 for 
acute whereas table 21 for chronic CVD event prediction respectively.  
Table 20: Accuracy Metrics for External Validation of Acute CVD Event Prediction 
Model 
 
 
 
As observed in table 20 above, a c-statistic of 0.7114 suggests that the original 
model trained using 2005—2015 training data performs well in predicting a future external 
2016-2017 data. The accuracy of 78.30% suggests that the model predicts the new 
outcomes based on the currently trained model well. This suggests that our predictive 
model is quite robust in predicting future outcomes.  
Metric Value 
c-statistic 0.7114 
Accuracy 0.7830 
Sensitivity 0.9373 
Specificity 0.2856 
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Table 21: Accuracy Metrics for External Validation of Chronic CVD Event 
Prediction Model 
 
 
    
 
As observed in table 21 above, a c-statistic of 0.5795 suggests that the original 
model trained using 2005—2015 training data does not perform well in predicting future 
external 2016-2017 data. The accuracy was 85.26% which suggests that the model 
predicted 85.26% of the outcomes accurately based on the current data . This suggests 
that our predictive model is somewhat robust in predicting future outcomes. This also 
suggests that there could have been some overfitting involved with the random forest 
model since it performs extremely well on the training sample although not quite accurate 
on validating externally. The chronic  CVD random forest model was thus more prone to 
overfitting as compared to the acute CVD event random forest model.  
The heat maps depicted in figures 15 and 16 below summarize all the prediction 
metrics that we compared for the machine learning and regression models. Figure 15 
summarizes the metrics for acute CVD events whereas figure 16 summarizes the same 
for chronic CVD. The figures are color coded as per the value for the metric with green 
indicating a very high value which indicates a better model, followed by yellow for a 
moderate value indicating a moderate metric and red indicating a relatively poor value. As 
seen from these values, most of these models performed poor on their specificity values. 
This suggests that these models along with identifying those with a positive result 
accurately would also give a lot of false positives. Literature suggests that usually tests 
with a high sensitivity also have a high specificity value associated.29 From a clinical 
Metric Value 
c-statistic 0.5795 
Accuracy 0.8526 
Sensitivity 0.8540 
Specificity 0.3050 
67 
 
standpoint identifying more false positives would however be better than identifying 
someone with a disease as false negative. This would help in taking the necessary 
precaution irrespective rather than neglecting care.  
    
        *RF – Random Forest 
Figure 15: Heat Map Depicting Prediction Metrics For Acute CVD Events Models 
 
 
 
           
         *RF – Random Forest 
 
Figure 16: Heat Map Depicting Prediction Metrics For Chronic CVD Models 
 
 
 
 
 
 
Predictive Models (Acute) c-statistic Accuracy Sensitivity Specificity
Standard regression 0.7534 0.7928 0.9251 0.3357
GLM Net 0.7853 0.8028 0.9846 0.2447
Random Forest 0.9738 0.9754 0.9996 0.9771
Gradient Boosting 0.7833 0.8065 0.928 0.3448
Deep Learning 0.8267 0.8345 0.9345 0.3444
RF* Internal validation 0.6808 0.7715 0.8597 0.485
RF External validation 0.7114 0.783 0.9373 0.2856
Predictive Models (Chronic) c-statistic Accuracy Sensitivity Specificity
Standard regression 0.7641 0.8098 0.9089 0.556
GLM Net 0.7349 0.7787 0.9473 0.5552
Random Forest 0.9872 0.9888 0.9914 0.9452
Gradient Boosting 0.7608 0.7713 0.9808 0.3075
Deep Learning 0.7662 0.7753 0.9878 0.3122
RF* Internal validation 0.5488 0.6585 0.8235 0.2742
RF External validation 0.5795 0.8526 0.854 0.305
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Aim 1d: To create an interactive web-based application using the R-shiny to predict 
the risk of CVD among cancer patients using the most accurate model identified 
 The most accurate model as identified above was the random forest model. This 
model was then used to build a dynamic web-based application using the most significant 
predictors summarized in tables 12 and 13 by the random forest model for acute and 
chronic CVD models. This application can then be used by the physicians to evaluate the 
risk of CVD in cancer patients given the information about the predictors that are in the 
application. The most important predictors like those identified above for a chronic CVD 
condition and those identified for an acute CVD condition were used to build the web-
based application. Two separate web-based applications were built for predicting the 
probability of a chronic and acute CVD event among cancer patients. One for predicting 
the risk of acute CVD whereas another to predict the risk of chronic CVD events. In addition 
to those identified in tables 12 and 13, the web-based application also included some basic 
sociodemographic characteristics that the physician might want to ask their patients in any 
case.  
Following are the web-based applications built using the above-mentioned predictors 
on the R Shiny app as shown in figures. These are dynamic and predict the probability of 
acute/ chronic CVD given the combination of input values for the predictors.   
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Figure 17: Web-Based Application to Predict the Risk of Chronic CVD In Cancer Patients 
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Figure 18: Web-Based Application to Predict the Risk of Acute CVD In Cancer Patients 
 
 
71 
 
DISCUSSION: 
 We characterized our study population that were cancer patients with and without 
CVD based on sociodemographic characteristics. We found that age, marital status, 
education and employment status differed significantly across cancer patients with and 
without CVD. However, we suspected that given the wide range of confidence intervals, 
this could have been due to a low sample size in specific groups as compared to reference 
groups. As observed from our study, the machine learning algorithms were more accurate 
in predicting the CVD risk in cancer patients as compared to the conventional stepwise 
regression method. It was observed that the c-statistic obtained was lower for the 
conventional regression methods for acute and chronic CVD prediction models both. The 
model built for predicting acute CVD events was more accurate as compared to chronic 
CVD prediction model. On conducting internal and external validation as well, it was 
observed that the chronic CVD prediction model was less accurate as compared to acute. 
Our validation techniques suggest that future work could be done on both the acute and 
chronic models to incorporate more predictors to make the model more generalizable and 
valid that can then increase the usefulness of prediction models. Adding some more 
predictors that can account for the regional differences might help in increasing the validity 
and usefulness of these models. Overall prediction was more accurate with the models 
built using machine learning algorithms as compared to those built using conventional 
stepwise regression approach. 
 Some previous studies have looked at application of machine learning algorithms 
to prediction of CVD risk as compared to the conventional approaches. A study conducted 
by Weng et al., found similar results to our study where the machine learning algorithms 
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improved prediction in comparison to already existing approaches.4 Neural networks were 
the highest achieving algorithm in terms of accuracy. This study was however conducted 
in general population and was not restricted to cancer patients. In addition, it was also 
restricted to routine clinical data from family practices which limits the generalizability.  
A study conducted by Goldstein et al. also looked at cardiovascular risk prediction 
using machine learning algorithms. This study also suggested that machine learning 
algorithms are more advantageous when it comes to generating a predictive model as 
compared to traditional regression approaches.30 This was similar to the findings in our 
study. The prior study was however not specific to cancer patients.  
A study conducted by Dranitsaris et al., similar to our study, developed a predictive 
model to estimate cardiotoxic risk in cancer patients. It was however restricted to breast 
cancer patients receiving anthracyclines thus limiting the generalizability. They used 
generalized estimating equations (GEE) model along with nonparametric bootstrapping to 
develop the predictive models. The c-statistic obtained was 0.84 which suggests that it 
was a good model. Similar to our results, this study suggested that machine learning 
models have good predictive capacity.9 However this study did not compare the accuracy 
to multiple other machine learning algorithms or conventional regression models. Thus, 
they lacked a comparison to conventional approaches which used standard regression 
techniques.  
However, there have been studies in the literature conducted by Christodoulou et 
al. and Gravesteijn et al. that have compared machine learning algorithms to regression 
models for clinical prediction.31,32 These studies suggested that machine learning 
algorithms performed no better than regression models. However in our study, as 
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observed from the results for cancer population, the c-statistics obtained for ML models 
were higher compared to the standard regression models. Although, all other ML models 
except for random forest had a c-statistic close to each other and to the standard 
regression model. However, external validation for a random forest model suggested that 
specifically for a chronic CVD model, the model was not quite robust in predicting future 
outcomes. This suggests that there could be some overfitting involved with the chronic 
CVD random forest model which could be the reason for a very high c-statistic. This was 
also suggested in the study conducted by Gravesteijn et al. where the random forest model 
was more prone to overfitting. The authors also implied that prediction models need 
continuous updating and validation because their performance is often worse in newer 
cohorts which was also observed in our study.32   
 The major strength of our study is that it is one of the first studies to explore the 
application of machine learning approaches to predict the risk of CVD in cancer patients 
comparing that to the traditional regression approach. There have been some studies in 
the literature looking at CVD outcomes in  cancer patients. However, these studies have 
mainly been from diagnostic purposes quantifying calcifications and other clinical 
outcomes obtained from X-rays and CT scans. These have used algorithms such as deep 
learning, neural networks and noisy-threshold classifier to predict outcomes and suggest 
that they are superior in comparison to standard regression approaches. Our study used 
a nationally representative sample which increases the generalizability of aim 1A results 
where adjusted analyses was conducted using complex survey weights. Since the models 
developed are predictive, they would help in managing the cardiovascular outcomes of 
cancer patients more efficiently.  The web-based application built to dynamically predict 
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the risk of CVD in cancer patients given all the predictors would help the physicians in 
tailoring the interventions based on the results.  
 However, the study also has certain limitations. Firstly, the models were trained on 
cross-sectional data. Certain time dependent variables, that would have been available if 
it were a longitudinal dataset could not be controlled. Secondly, since the dataset was 
cross-sectional, certain lifestyle characteristics were assumed to be the same at the time 
of cancer diagnosis even if the patients were now in remission. Thirdly, the risk factors for 
certain CVD conditions differ innately which was why separate models were built for 
chronic and acute CVD events. There could also be some differences in the risk factors 
involved in myocardial infarction, angina, coronary artery disease and other heart diseases 
which were all clubbed as ‘Chronic’ CVD events due to sample size limitations and ease 
of interpretability. In addition, certain variables such as specific cancer therapy used, and 
cancer type had high missing values. Cancer therapy could be broadly classified into 
chemotherapy, surgery and radiotherapy used which was then used in the study along 
with the specific cancer therapy variable. The missing values for cancer type were recoded 
using KNN imputation, however the percentage of missing values could lead to some bias 
in the study. Finally, MEPS data being self-reported could lead to some recall and selection 
bias. However, this would be minimized since AHRQ also verifies the patient medication 
and medical conditions reports from their physicians and their pharmacists.12 There could 
also be some coding errors involved if the providers did not code the ICD-9 codes for 
patient diagnoses accurately. In addition, we also made an assumption that all the patients 
with comorbidities and certain CVD risk factors such as high blood pressure and 
cholesterol have accurate diagnosis in the datasets. It is possible that some might have 
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these diagnoses without having an actual code in the file, however these would be 
misrepresented in our analyses as ‘No’ or ‘Missing’. 
 Despite the limitations stated above, the strengths and the novelty involved in the 
approach makes it a strong study and adds a lot to the literature. Our study results suggest 
that the use of novel techniques such as machine learning might be more beneficial than 
the conventional approaches in predicting outcomes. The model accuracy results might 
help in guiding certain real-world evidence analysis approaches especially in this era when 
the field is moving more towards data innovation.  Our internal and external validation 
models suggested that there might be overfitting involved in the random forest chronic and 
acute CVD models, although future model calibration can increase the usefulness and 
validity of these models. Even though our models did not perform the best on conducting 
validation, they did suggest that they had more predictive power than the standard 
regression techniques (higher c-statistic). Our study is a good starting point to suggest the 
use of machine learning algorithms in evaluating healthcare outcomes as more data 
becomes available. With more data and long-term outcomes available, the validity of our 
models can be increased to be made more useful for real-world application. The predictive 
power of these models can be used to a great extent in planning future treatment plans for 
cancer patients given their cardiovascular risks. The web-based application that we 
created might help the physicians in giving a real time estimate  of the cardiovascular risk 
cancer patients. Based on the predicted cardiovascular risk, the physicians can monitor 
the cardiovascular health of cancer patients more efficiently. It can also guide certain 
developers to create more web-based and mobile applications to make healthcare more 
efficient. Down the line, it might help in managing the CVD condition more efficiently and 
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have better health and cost implications for cancer patients. With more data and calibration 
these models can be made more robust for use in the real world.  
APPENDIX: 
 
 
 
 
Figure 1: Regularization pathway for acute CVD GLMNET model 
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Figure 2: Regularization pathway for chronic CVD GLMNET model 
 Thus, as seen from the figures above, the mixing percentages of 0 and 1 indicate 
the alpha values whereas the X-axis (regularization parameter) indicates the lambda 
values. The figures above suggest that for both the acute and chronic CVD models α = 0 
performs better than α = 1 since the ROC values obtained for the former are constantly 
higher than those obtained for the later. This indicates that a ridge regression would be 
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better for both acute and chronic CVD prediction models as compared to a lasso 
regression. The regularization path obtained for both the models suggest that, as we 
increase the penalty on the model (going from right to left) and decrease the complexity of 
the model, most of the regression coefficients tend to move towards 0 and being 
nonsignificant. Thus, a simpler model would probably be more accurate in making 
predictions as compared to a more complex model.  
 
Figure 3: Batch normalization deep learning curves for acute CVD prediction 
model 
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Figure 4: Batch normalization deep learning curves for chronic CVD prediction 
model 
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CHAPTER 3: BENEFIT-RISK ASSESSMENT OF BREAST 
CANCER THERAPIES USING MCDA MODEL 
 
BACKGROUND: 
Patients with cancer have an increased burden and a reduced quality of life majorly 
due to the associated comorbidities.1 Cardiovascular diseases are one of the major 
comorbidities associated with cancer patients. The prevalence of cardiovascular diseases 
(CVD) in cancer patients is growing making CVD one of the most associated comorbidity 
in cancer patients.2 In cancer patients, the CVD mortality rate has increased by 20-30% in 
recent years, whereas the cancer mortality rate has decreased by 20-30%.3 With growing 
concerns of CVD in cancer patients, it has become more important to consider cancer 
treatment related factors that put patients at an even higher risk. There are multiple factors 
that put cancer patients at an even higher risk for developing CVD that include, patient 
demographics, lifestyle factors and cancer treatment related factors.4,5 With increasing 
availability of cancer therapies, it would be important to focus on cardiovascular 
implications of therapies for planning the patient’s treatment plan more efficiently. Certain 
cancer treatments have been established to be more cardiotoxic than the others. Cardiac 
complications are specifically higher if  patients are receiving anthracyclines, radiotherapy 
or certain targeted therapies.6,7 These targeted therapies usually form the first line 
treatment regimens for cancer patients. These cardiotoxic effects of therapies can be seen 
even after years of being diagnosed with cancer or after  remission. 2 These targeted 
therapies are however also associated with an  higher overall survival in cancer patients.8 
It is thus necessary to assess the cardiotoxic and other adverse events profiles of such 
therapy regimens including targeted therapies to quantify the trade-off between adverse 
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events and survival. Assessing these outcomes might help the physicians in planning the 
treatment better. 
Evaluating specific characteristics associated with cardiotoxic adverse events 
would help in managing/ preventing the condition and tailoring cancer therapies 
appropriately. There have been some studies looking at cardiotoxic potential of specific 
drugs,9-11 however, characteristics associated with these therapies have not been 
described yet. Most of these drugs that have a high cardiotoxic potential are used in breast 
cancer patients.9-11 Focusing on breast cancer patients would thus be more informative 
and useful. Identifying combinations of drugs and therapy characteristics used in breast 
cancer treatment could help in understanding if there is a synergistic effect of multiple 
factors involved. If certain therapy related characteristics such as dosage or route of 
administration turn out to be associated with the increased potential of cardiotoxicity, the 
results can inform the physicians to be cautious respectively. The targeted therapies used 
in breast cancer treatment are also associated with a higher survival among cancer 
patients.10 Efficacy and tolerability which could be measured in terms of survival and 
adverse events are the two important considerations by physicians for treatment choices.12 
Given that these therapies have higher risks and higher survival both there would be an 
uncertainty in decision-making while prescribing. Consolidating these benefits and risks 
together in a model might be beneficial to make the decision-making easier. Conducting a 
benefit-risk assessment of these therapy regimens used in HER 2 positive patients  would 
help in consolidating and quantifying the benefits (survival) and risks (cardiac 
complications along with  other adverse events) outcomes in a single model. Breast cancer 
being one of the most prevalent cancer with cardiotoxic potential, a benefit-risk 
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assessment of therapies involved in breast cancer patients would immensely help 
physicians in decision-making.  This can be achieved using a Multiple Criteria Decision 
Analysis (MCDA)  model to attempt to reduce the uncertainty involved in decision-making.  
This model can be used to evaluate the trade-off between the therapy regimens that are 
usually used in HER 2 positive breast cancer patients by consolidating the benefits and 
the risks criteria.  
A MCDA model can be built using multiple perspectives namely, benefit-risk 
assessment, health technology assessment (HTA), portfolio decision analysis (PDA), 
commissioning decisions, shared decision making (SDM), and prioritizing patient’s access 
to health care. 13 HTA bodies use MCDA to make coverage decisions, PDA is conducted 
by scientific companies to choose the criteria where best to direct R&D efforts, 
commissioning decisions are mainly used to assess resource allocation whereas SDM 
and patient’s access models incorporate criteria that would be more important and 
subjective to patients such as quality of life, treatment satisfaction, etc.13 However, given 
that there is a survival-adverse events trade-off involved in the therapy alternatives, it 
would be the most appropriate to build a MCDA model from a benefit-risk assessment 
perspective.  MCDA modeling technique from this perspective is a way of incorporating 
benefits and risks and evaluating alternative treatment options at once by including the 
therapy regimens. The decision-making process can be made more transparent by 
describing the risks and benefits trade-off in a formal manner. MCDA provides a framework 
for systematic and replicable analyses of complex decision problems involving value trade-
offs. 13 Survival and cardiac implications of targeted therapies have not been studied as a 
value trade-off in combination with other conventional therapies as a part of standard 
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regimens. Most of the studies in the current literature have only looked at one targeted 
therapy at a time and its effects on population outcomes.6-11 These outcomes were also 
studied separately in separate studies and these have not been comparative across 
various therapy regimens. 6-11 Just looking at one targeted therapy at a time from a clinical 
utility/ decision-making standpoint would not be sufficient since in the real world these are 
usually given in combination with other therapies. A comparison between therapy 
regimens that include these specific drugs would thus be a fair comparison for MCDA 
model. Targeted therapies such as trastuzumab and pertuzumab although improve 
survival in HER 2 positive breast cancer patients, they also increase the risk of adverse 
events. 6,9  For HER 2 positive breast cancer patients NCCN guidelines enlist certain first-
line therapy regimens such as trastuzumab in combination with a taxane, trastuzumab in 
combination with a pertuzumab and a taxane and trastuzumab in combination with 
cyclophosphamide/ carboplatin and a taxane.14  These therapy regimens can be used as 
model alternatives while building a MCDA model. There is also enough evidence on these 
regimens like summarized in Table 25 below to conduct a benefit-risk assessment using 
MCDA model. A MCDA model incorporating the benefits and risks of therapy regimens 
used in HER 2 positive breast cancer patients might help in providing evidence to make 
the decision-making process more transparent. There is a high demand for transparency 
in healthcare decision making with the availability of growing and emerging options and 
the fields becoming more multidisciplinary. This demand for transparent decision 
processes can be fulfilled by a systematic construct of benefit-risk assessment. 15  A MCDA 
model helps in structuring various outcomes/ preferences together and systematically 
integrating these into a decision-making process. By assigning scores and weights to 
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different measures considered in the MCDA model and reporting these systematically in 
the model structure it can formalize the decision-making process. In the field of oncology 
which is highly multidisciplinary use of an MCDA model can help immensely in decision-
making. 16 It would help in choosing from the  three standard therapy regimens in HER2 
positive breast cancer patients like mentioned above. The objective of our study was to 
compare these therapy regimens with respect to their benefits and risks criteria that would 
be mentioned in the MCDA model below. 
Literature Review: 
We conducted  a literature review to identify studies that have looked at the 
application of a decision-making framework like multiple criteria decision analysis to 
conduct a benefit risk assessment of cancer therapy regimes. We also looked at studies 
that  evaluated patient preferences in choosing a cancer treatment. The following search 
strategy using a combination of MeSH terms was used:  ((((((("Molecular Targeted 
Therapy"[Majr])) OR "Drug Therapy"[Mesh:NoExp])) AND (((benefit risk) OR risk 
assessment) OR multiple criteria decision analysis)) AND "Neoplasms"[Majr])).The titles 
and abstracts were then screened for their eligibility using the following inclusion/exclusion 
criteria. 
We included studies that looked at a risk-benefit trade off associated with a cancer 
therapy and considered cardiotoxicity as at least one of the risk factors under 
consideration. We also restricted our search to studies conducted in humans and 
published in English. We excluded studies that focused just on risks or just on benefits. 
We also excluded studies that did not look at cardiotoxic risk. We excluded studies that 
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were conducted in pediatric population or were narrative reviews and did not look at any 
outcomes. 
 The search strategy resulted into 97 studies. On applying the inclusion/exclusion 
criteria, 94 articles were excluded. The final literature review included three studies.17 - 19 
Figure 19 below includes a PRISMA flowchart of studies that were included in the literature 
review.  
 
 
 
 
 
 
 
 
Figure 19: PRISMA Flowchart of Literature Review (Aim 2) 
 
Table 22 below summarizes the studies that were included in the literature review. 
There were only 3 studies that looked at a benefit-risk trade off associated with cancer 
therapies. Majority of the studies in literature are narrative reviews that define the steps 
involved in MCDA. There are very few studies that have conducted a structured decision-
making process to quantify the benefits and risks associated with cancer therapies.  
Total results through databases searching (n= 97) 
Abstracts reviewed for eligibility (n=16)  
Studies included (n= 3) 
Remove duplicates (n=9) 
Articles excluded (n=13): 
Not looking at any cardiac 
complication as a risk at all 
(n=6) 
Reviews (n=7) 
 
Articles screened for eligibility (n=88) 
Articles excluded (n=72) since 
they did not include any benefit-
risk or value trade off and 
focused on clinical outcomes 
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 Table 22: Summary Of Literature Review (Aim 2) 
  
There are only three studies that have looked at application of decision making 
models to explore patient preferences in choosing the treatment alternatives in cancer 
patients. In a study conducted by Postmus et al. it was suggested that progression-free 
survival (PFS) was weighted higher (0.54) than severe life-threatening toxicities (0.32) for 
patients with multiple myeloma. This preference for PFS was irrespective of other factors 
included in the model. This study was however restricted to a small sample size and did 
not compare different cancer treatment options. The study focused on patient preferences 
for PFS over adverse events and did not compare these risks and benefits across 
treatment alternatives.17  
Wagner et al. also applied the MCDA framework in eliciting patient preferences. 
The EVIDEM-derived MCDA framework was used in the study where five patients and six 
physicians assigned criteria weights. This study was thus conducted from a shared 
decision-making perspective. The participants individually weighted the relative 
importance of the criteria on the basis of what mattered the most and least to them when 
making a decision on the cancer management options. Similar results were obtained in 
Study Study Objective 
Postmus et al., 201817 To elicit the preferences of patients with multiple myeloma 
regarding the possible benefits and risks of cancer treatments 
Wagner et al., 201818 To apply MCDA shared-decision framework to explore what 
matters to patients in considering the treatment options 
Lifford et al., 201519 To understand older women’s decision making and coping in 
context of breast cancer treatment 
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this study where patients preferred treatment over watchful waiting (weight 0.32 vs 0.24) 
with the largest contribution from PFS (weight = 0.11) over fatal adverse events (weight = 
0.06) and impact on health-related quality of life (weight = 0.04). 18 This study also focused 
on patient preferences for criteria rather than ranking therapy alternatives.  
A study conducted by Lifford et al. looked at decision-making process of older 
breast cancer women in coping with cancer treatment.19 Semi-structured interviews were 
carried out with older women to assess women’s information and support needs, their 
breast cancer diagnosis and treatment decisions. The authors found that past experience 
of cancer and its treatment, benefits and the risks associated with these treatments were 
all ranked important from a patient’s perspective. Women also described various strategies 
to cope with breast cancer and their treatment decisions. These included seeking 
information, obtaining practical and emotional support from healthcare professionals, 
friends and relatives, and relying on personal faith.19 Like the previous studies, this study 
was also mainly conducted to elicit patient preferences in making a treatment decision. 
As seen from these studies, they were from a patient’s decision-making perspective 
and there is no clear consensus on choosing a specific therapy regimen given the benefit-
risk trade off. These were conducted mainly to elicit the factors that patients might consider 
important while making a decision about a therapy alternative.  
Gaps in the literature: 
As seen from the above literature, there is a lack of evidence of studies that 
incorporate the benefits and risks of cancer therapies together in a model to assign values 
and make the decision process more transparent.  In cancer care, multidisciplinary teams 
have to work together to create patient’s treatment plan which makes decision-making 
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even more difficult, especially if it is carried out in an informal non-transparent manner. 
This makes the need for a more transparent decision-making process like MCDA even 
greater in oncology.16 Currently for HER 2 positive breast cancer patients, the physicians 
usually prescribe trastuzumab with an additional chemotherapeutic agent that is tailored 
as per the patient needs with the aim of prolonging survival. 20 It mainly depends on clinical 
characteristics such as patient’s tumor type, size and stage of cancer. 21 With reports of 
adverse events growing, taking survival and adverse events both into consideration while 
treatment planning becomes equally important. However, there are no standardized 
decision-making guidelines that can formalize this process which may increase conflicts 
that are inherent to clinical decision making.  With multidisciplinary teams involved, a 
guided approach to decision-making might help decision‐makers, providers and patients 
in deliberation and communication.16 Stating the criteria considered while making the 
decision explicitly and scoring and weighting these, might increase the transparency of the 
process. 
Current studies that have used MCDA modeling techniques have only looked at 
patient preferences for the criteria (Table 22) and there are no studies that look at value 
assessment of cancer therapies from a benefit-risk perspective. Current studies are mainly 
conducted using a decompositional approach where criteria weights were derived later 
based on the therapy alternative that the patients preferred. 17-19 They were from a patient 
perspective to evaluate the criteria that the patients considered most important while 
making a decision and hence mainly only include patient reported criteria such as 
satisfaction with the treatment, quality of life, etc. This helps in ranking the criteria rather 
than ranking the therapy alternatives. We wanted to develop a model that can rank the 
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therapy alternatives given the inputs on the criteria that would be identified from the 
literature mainly from a physician decision-making perspective.  Developing a MCDA 
model using a compositional approach would help in assigning a value to each breast 
cancer therapy regimen using the evidence in the literature for criteria inputs. This might 
then help the physicians and multidisciplinary teams in making a decision. Targeted 
therapies (trastuzumab and pertuzumab in HER 2 positive breast cancer patients) as 
suggested are associated with a higher survival as well as a higher cardiotoxic potential 
which makes choosing the therapy alternative difficult. Most of these targeted therapies 
associated with a higher survival and cardiotoxic profile are used in breast cancer 
patients.6,9 Most of the clinical studies conducted looking at these outcomes have also 
been in breast cancer patients. Thus more evidence is available to conduct a benefit-risk 
assessment of breast cancer therapy regimens using a MCDA model. Our goal of study 
was thus to develop a Multi Criteria Decision Analysis Model (MCDA) to evaluate benefits 
and risks associated with breast cancer therapy regimens. Literature inputs were used to 
assign a value with each regimen and rank these to make decision-making easier.  
Specific Aim 2: 
To assess cardiotoxicity associated with targeted therapies as compared to non-
targeted therapies and develop a model to conduct benefit-risk assessment of therapy 
regimens in breast cancer patients  
d. To describe the cancer therapy characteristics associated with the cardiotoxic 
adverse events in breast cancer patients receiving targeted therapies as 
compared to those receiving non-targeted therapies and evaluate the drug-
event association using a disproportionality analysis 
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e. To develop a Multi Criteria Decision Analysis (MCDA) model to conduct benefit-
risk assessment of breast cancer therapy regimens 
f. To conduct sensitivity analyses to assess the MCDA model performance and 
uncertainty in the model 
METHODS AIM 2: TO ASSESS CARDIOTOXICITY ASSOCIATED WITH TARGETED 
THERAPIES AS COMPARED TO NON-TARGETED THERAPIES AND DEVELOP A 
MODEL TO CONDUCT BENEFIT-RISK ASSESSMENT OF THERAPY REGIMENS IN 
BREAST CANCER PATIENTS 
Aim 2a: To describe the cancer therapy characteristics associated with the 
cardiotoxic adverse events in breast cancer patients receiving targeted therapies 
as compared to those receiving non-targeted therapies and evaluate the drug-event 
association using a disproportionality analysis 
Data Source:  
FDA Adverse Event Reporting System (FAERS) quarterly files from 2005 to 2015 
were used for this study aim. These files were downloaded from the public dashboard as 
a zip file which were then extracted for analyses. FAERS is a voluntary, spontaneous 
reporting database that provides information on adverse event and medication error 
reports submitted to the U.S. FDA by healthcare professionals, consumers, and 
manufacturers worldwide.22 FAERS quarterly files contain information on demographics 
and administrative information along with the initial report for the patients, drug and 
reaction information from the reported adverse events case reports and patient 
outcomes.22 Files DRUGyyQq.txt and THERyyQq.txt were used to identify targeted and 
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non-targeted therapies and to identify the duration of these therapies. REACyyQq.txt files 
were used to identify cardiovascular adverse events. OUTCyyQq.txt files were used to 
identify the severity of the cardiovascular adverse event. Patient characteristics were 
obtained from the DEMOyyQq.txt files. These files were event-level files that were used to 
identify cardiotoxic and non-cardiotoxic reported adverse events in breast cancer patients.  
Proposed study design and sample:  
 Cross sectional study design was used for this study aim. The study sample 
consisted of adverse events identified in  breast cancer patients over the age of 18 years 
in the US from 2005-2015. INDIyyQq.txt files contain patients’ disease information, which 
were used in our study to identify breast cancer patients. Medical Dictionary for Regulatory 
Activities (MedDRA) preferred terms (variable PT) were used to identify breast cancer 
patients. These MedDRA terms were coded as strings of words to identify any particular 
cancer type. The string ‘breast cancer’ was used to identify the study sample. The string 
search identified breast cancer patients and excluded those who just reported cancer pain 
without any specific diagnoses. Using the breast cancer string resulted into a sample size 
of 35,630,544 events identified in breast cancer patients from FAERS 2005-2015 files.  
Study Variables: 
Certain patient-related characteristics such as patient’s age, gender, death date 
and the time of patient’s visit the reaction was reported were identified from FAERS files. 
Cardiovascular adverse event related factors that were identified were the reporter’s type 
of occupation, the adverse event date, preferred terms to identify the specific cardiotoxic 
events, severity of the adverse event outcome and if the adverse event reaction stopped 
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on discontinuing the drug or if it recurred on initiating the drug again.  The drug related 
factors identified from different FAERS files were the specific drug/ targeted therapy name, 
the role of the drug in the adverse event, route of administration, therapy start/ end date, 
therapy duration and certain dosage related characteristics such as dosage amount, unit, 
form and frequency. The targeted therapies used in HER2 positive breast cancer patients 
were identified using terms such as ‘Trastuzumab’, ‘Ado-trastuzumab’, ‘Herceptin’, 
‘Kadcyla’,  ‘Pertuzumab’ ,’Perjeta’, ‘Lapatinib’, ‘Tykerb’, ‘Neratinib’, ‘Nerlynx’, ‘ Tucatinib’ 
and ‘ Tukysa’. These targeted therapies were chosen based on the guidelines 
recommended by American Cancer Society specific to targeted therapies used in HER 2 
positive breast cancer patients.23  All the variables identified from FAERS to be included 
in the study (patient characteristics, cardiovascular adverse event related factors and drug 
related factors) are summarized in Table 23 below. 
Table 23: Study Variables for Aim 2A identified from the FAERS 2005-2015 
database 
Variable Variable description 
Patient characteristics: 
-AGE_COD 
-GENDR_COD 
-DEATH_DT 
-I_F_COD 
 
-Age 
-Gender 
-Patient’s death date 
-Initial/ follow up code 
Cardiovascular adverse event related 
factors: 
-OCCR_COD 
 
-EVENT_DT  
-PT (string searches for ‘Myocardial 
Infarction’, ‘Arrhythmia’, ‘Cardiac 
Failure’, ‘Cardiac signs and symptoms’ 
and ‘Myocardial Disorders’ 
-OUTC_COD 
 
 
-DECHAL 
 
 
-Reporter’s type of occupation (physician, 
pharmacist, other health professional, etc.) 
-Adverse event date 
-Preferred term to identify cardiovascular 
adverse event 
 
 
-Patient’s adverse event outcome (death, 
life threatening, hospitalization, disability, 
required intervention, other serious event)  
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-RECHAL 
 
-Reaction stopped on stopping the drug 
therapy 
-Reaction recurred on restarting the drug 
therapy 
Drug related factors: 
-DRUGNAME 
 
 
-ROLE_COD 
 
-ROUTE  
-DOSE_AMT/ DOSE_UNIT/ 
DOSE_FORM/ DOSE_FREQ 
-START_DT/ END_DT 
-DUR_COD 
 
-Chemotherapeutic drug name and also to 
identify other drugs that were given along 
with it 
-Role of the drug (primary/ secondary 
suspect drug, concomitant or interacting) 
-Route of administration 
-Dosage amount, unit, form and frequency 
 
-Therapy start and end date 
-Therapy duration 
 
Statistical Analyses:  
Descriptive analyses were used to summarize the cancer therapy characteristics 
associated with cardiovascular adverse events. Frequencies and means were used to 
summarize categorical and numerical variables respectively. Disproportionality analyses 
was conducted to confirm a potential association between a specific cancer drug and a 
cardiovascular adverse event.24 This analysis was conducted using a logistic regression 
model for bivariate and multivariate analysis. The odds ratios that are derived using these 
logistic regression models (bivariate and multivariate) are referred to as reporting odds 
ratios when looking at specific drug-adverse event pairs. Disproportionality analyses with 
reporting odds ratios (ROR) was used to evaluate the magnitude of event signals in the 
FAERS. Cases were reports of cardiotoxicity events and non-cases were all reports of 
adverse events other than cardiotoxicity. The ROR for disproportionality analysis was 
calculated using a case/non-case method using the formula stated below. 
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ROR = a / b 
            c / d 
where, a = Cardiotoxic adverse events reports within those receiving targeted therapy 
b = Non-cardiotoxic adverse events reports within those receiving targeted therapy 
c = Cardiotoxic adverse events reports within those not receiving targeted therapy 
d =Non-cardiotoxic adverse events reports within those not receiving targeted 
therapy 
 
              The ROR is estimated as the odds of cardiotoxicity in those exposed to each 
cancer drug divided by the odds of cardiotoxicity in those not exposed to the drug of 
interest (all other drugs in the database). A significant disproportionality, or in other words 
a possible signal was defined as the lower bound of the 95% confidence interval (95% CI) 
exceeding 1. Once the bivariate association was established using the disproportionality 
approach, a logistic regression model was built accounting for other covariates. These 
cancer therapy related characteristics were defined by using all the other variables 
mentioned in Table 23. 
Aim 2b: To develop a MCDA model to conduct benefit-risk assessment of breast 
cancer therapies 
Multiple criteria decision analysis (MCDA) model was used for comparative benefit-
risk assessment of breast cancer therapy regimens that cause cardiotoxicity. The 
indication considered in our study to define the decision problem was breast cancer 
therapy regimens. Based on the cardiotoxicities involved, trastuzumab-based therapy 
regimens were chosen to be included in the model since these were the most cardiotoxic.25  
Most of the literature available on benefits and risks associated with therapies was 
surrounding breast cancer therapy regimens including trastuzumab. 26-36 There was thus 
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enough evidence to build a MCDA model evaluating breast cancer therapy regimens. The 
data needed for MCDA model or the model inputs were thus entirely obtained from the 
literature. 26-36  The alternatives under consideration were breast cancer therapy regimens 
that are associated with highest cardiotoxic potential but also improve cancer 
outcomes/survival. The three breast cancer trastuzumab-based therapy regimens 
considered were namely, trastuzumab with a taxane, trastuzumab and pertuzumab with a 
taxane and trastuzumab with cyclophosphamide/ carboplatin along with a taxane. These 
specific regimens were chosen based on the NCCN treatment guidelines and available 
evidence in the literature for breast cancer patients.14 These are the first line breast cancer 
therapies that are used in HER 2 positive patients and had enough literature evidence for 
the MCDA model with respect to the benefits and the risks criteria. We also met and 
discussed these regimens with a pharmacist at VCU, Dr. Erin Hickey who specializes in 
oncology treatment. On consulting with her and scanning the literature for available 
evidence on similar groups of HER 2 positive breast cancer patients, we finalized our 
therapy alternatives for the MCDA model.  Specific drugs under each therapeutic category 
are summarized in Table 24 below. 
Table 24: Treatment Alternatives Considered in the MCDA Model 
 
 
 
 
The focus of the MCDA was on the benefit-risk assessment of breast cancer 
therapy regimens and the difficulty in choosing a first-line treatment. We focused on the 
Treatment alternative Specific therapy 
 
Targeted therapy Trastuzumab 
Pertuzumab 
 
Taxanes Paclitaxel 
Docetaxel 
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first-line treatment options since those would form the basis of your treatment plan and 
future decisions might depend on the outcomes of the first-line treatment. On further 
consulting with Dr.Hickey, we also decided to expand the criteria of our model to include 
other adverse events and not restrict to  cardiovascular implications of these therapies. 
These other adverse events such as diarrhea, peripheral neuropathy and febrile 
neutropenia might also have a major impact on decision-making. Our final model thus 
focused on survival and quality of life outcomes as benefits criteria and diarrhea, peripheral 
neuropathy and febrile neutropenia along with cardiovascular adverse effects as risks 
criteria. A set of nonoverlapping evaluation criteria were chosen to assess the risk/benefit 
outcomes. Figure 20 below represents the effects tree that summarized the criteria that 
were evaluated in the MCDA model. Effects tree is a technique used to organize and 
visualize the MCDA model that summarizes all the favorable/benefits criteria under one 
branch and all the unfavorable/risks criteria under another branch for the same therapy 
alternatives.13 Each of the criteria mentioned in the effects tree were scored and weighted 
to quantify the benefit-risk score associated with each of the alternatives in the model.  
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Figure 20: Effects Tree for the MCDA Model 
 
The model was thus built using favorable (overall survival, progression-free survival 
and quality of life {expressed as quality adjusted life years – QALY}) and unfavorable 
effects (number of cardiovascular adverse events, cardiovascular mortality, CVD related 
Risk-Benefit 
Assessment of Breast 
Cancer Therapy 
Regimens 
Benefits 
Risks 
Overall Survival 
Progression free 
survival 
Quality of Life 
(QOL)  
Cardiovascular 
mortality 
CVD hospitalization 
Any cardiovascular 
event 
Diarrhea 
Peripheral 
neuropathy 
Febrile neutropenia 
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hospitalizations, diarrhea, peripheral neuropathy and febrile neutropenia) criteria. A 
benefit-risk assessment was carried out using these favorable and unfavorable effects 
criteria. The performance of each of the therapy regimen alternatives (trastuzumab + 
taxane, trastuzumab + pertuzumab + taxane, trastuzumab + cyclophosphamide/ 
carboplatin + taxane) on the criteria mentioned above was evaluated using data from the 
literature. Similar studies from the literature were used to evaluate performance of therapy 
alternatives on each of these criteria by providing model inputs.26-36 A literature review was 
conducted to evaluate studies that have looked at benefits and risks associated with breast 
cancer therapy regimens. Our search strategy used a combination of terms such 
as  "Molecular Targeted Therapy" OR "Drug Therapy" AND “Survival” OR “Adverse 
Events” OR “Risks” OR “Benefits” AND "HER 2 positive”. We then evaluated all the studies 
by screening the titles and abstracts to include only those studies that have looked at the 
breast cancer therapy regimens that we were interested in as therapy alternatives for the 
MCDA model. We excluded studies that had a significantly different study population, 
specifically if they were looking at the specified therapy regimens adjuvantly with other 
treatment options such as anthracyclines, radiotherapy, or surgery. We also excluded 
studies that only reported clinical and laboratory outcomes. We included studies that 
reported results on criteria that were included in our MCDA model. After finalizing studies 
to provide model inputs, we also identified some more studies from the references of the 
pre finalized studies. The criteria for evaluating the cancer therapies using an MCDA 
model were further tuned and defined based on Dr.Hickey’s suggestions and the available 
literature evidence (Febrile neutropenia was added after evaluating literature since it was 
well reported) . Studies conducted by Swain et al., Li et al., Hajjar et al. and Garrison et al. 
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were used to input benefits criteria.26-29 Studies conducted by Swain et al., Advani et al., 
Tolaney et al., Schneeweiss et al., Woodward et al., Tanaka et al. and Hussain et al. were 
used to input the risks criteria.30-36 These are summarized in Table 25 below. The literature 
sources used to provide inputs for all of these criteria for each therapy alternative are 
summarized in Table 25 below. 
Table 25: Literature Sources for Model Inputs 
 
Model criteria Therapy alternatives Sources 
Benefits 
Overall Survival Trastuzumab + Docetaxel 
Trastuzumab + Pertuzumab + Docetaxel 
Docetaxel + Carboplatin + Trastuzumab  
Swain et al., 201526 
Swain et al., 201526 
Li et al., 201827  
Progression free 
survival 
Trastuzumab + Docetaxel 
Trastuzumab + Pertuzumab + Docetaxel 
Docetaxel + Carboplatin + Trastuzumab  
Swain et al., 201526 
Swain et al., 201526 
Li et al., 201827  
Quality of life 
(expressed as 
QALY) 
Trastuzumab + taxane 
Trastuzumab + Pertuzumab + chemotherapy 
Trastuzumab + Carboplatin + Docetaxel  
Hajjar et al., 201928 
Garrison et al., 201929 
Hajjar et al., 201928 
Risks 
CVD adverse events 
Cardiovascular 
mortality 
Trastuzumab + Paclitaxel 
Trastuzumab + Pertuzumab + Docetaxel 
Trastuzumab + Cyclophosphamide + Paclitaxel 
Swain et al., 201526 
Swain et al., 201526 
Advani et al., 202030  
CVD 
hospitalization 
Trastuzumab + Paclitaxel 
Trastuzumab + Pertuzumab + Docetaxel 
Trastuzumab + Cyclophosphamide + Paclitaxel 
Tolaney et al., 201531 
Schneeweiss et al., 201832 
Advani et al., 202030  
Any 
cardiovascular 
event* 
Trastuzumab + Paclitaxel 
Trastuzumab + Pertuzumab + Docetaxel 
 
Trastuzumab + Cyclophosphamide + Paclitaxel 
Tolaney et al., 201531 
Swain et al., 201526 
Woodward et al.,201933 
Advani et al., 202030  
Any other adverse event 
Diarrhea Trastuzumab + Paclitaxel Swain et al., 201734 
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Trastuzumab + Pertuzumab + Docetaxel 
Trastuzumab + Cyclophosphamide + Paclitaxel 
Swain et al., 201734 
Hussain et al., 201835 
Peripheral 
neuropathy 
Trastuzumab + Paclitaxel 
Trastuzumab + Pertuzumab + Docetaxel 
Trastuzumab + Cyclophosphamide + Paclitaxel 
Tolaney et al., 201531 
Woodward et al.,201933 
Tanaka et al., 201536 
Febrile 
neutropenia 
Trastuzumab + Paclitaxel 
Trastuzumab + Pertuzumab + Docetaxel 
Trastuzumab + Cyclophosphamide + Paclitaxel 
Swain et al., 201734 
Swain et al., 201734 
Hussain et al., 201835 
*The cardiovascular events evaluated were heart failure, dysrhythmia, ischemia or 
cardiomyopathy 
 
The effects tree was defined based on the outcomes mentioned in the studies 
above. A performance matrix (effects table) was built using the model inputs from the 
literature to describe the performance of each of the therapy alternatives on the  criteria 
mentioned. Performance matrix summarizes the extracted information from the literature 
with the outcome values (model inputs) for each therapy alternative under consideration.13 
These model inputs for each of the criteria across therapy regimens are summarized in 
Table 26 below which was the performance matrix for the MCDA model. 
Table 26: Model Inputs for the MCDA Model – Performance Matrix 
Regimen 1: Trastuzumab + taxane 
Regimen 2: Trastuzumab + Pertuzumab + taxane 
        Regimen 3: Trastuzumab + Cyclophosphamide/Carboplatin + taxane 
  
 
Criteria Regimen 1 Regimen 2 Regimen 3 
Overall survival (months)26,27 40.8 56.5 59.3 
Progression-free survival (%)26,27 78.8 70.6 84.6 
QALY28,29 16.17 15.57 15.02 
Cardiovascular mortality (%)26,30 29 36 0 
Cardiovascular hospitalization (%)30-32 3.2 16 61 
Any other cardiovascular event (%)26,30,31 0.5 18 2.8 
Diarrhea (%)34,35 43 59 54 
Peripheral neuropathy (%)31,33,36 13.1 56 12 
Febrile neutropenia (%)34,35 7 13 4.5 
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 These criteria were scored to enable comparison onto a common scale. Direct 
rating compositional scoring approach using partial value functions was used to score the 
criteria. The values from literature for each criterion were used as functions that were then 
scored giving the highest score to the best value and others relative to it. These scores 
have been summarized later in Table 32. There are multiple scoring techniques that can 
be used namely, visual analog scale (VAS), analytical hierarchy process (AHP), 
MACBETH and point allocation.37 All the other techniques are mainly used with  qualitative 
data or inputs where the criteria can be compared based on their categories. For VAS and 
point allocation, points or scores are assigned to alternatives in proportion to their relative 
importance on a criteria. AHP and MACBETH compare alternatives pairwise on each 
criterion to assess their importance and assign an average score of those comparisons. 
With qualitative categorical criteria it is easier to allocate these points and make pairwise 
comparisons. However with numerical values, it is not possible to make such comparisons 
since there are no categories within criteria to be compared.  With quantitative data that  
reports mean values and percentages, it is preferable to use direct literature inputs as 
partial functions and score the criteria. Other than these, if time and money are not an 
issue and it is feasible to conduct a study, decompositional scoring approaches can also 
be used to score criteria where overall value of the alternative is assessed to begin with 
and scores and weights are then derived from these. Discrete choice experiment is a 
decompositional approach where the recruited study sample rank their alternative first and 
later specify the most important criteria they considered while making the choice. However, 
designing a discrete choice experiment requires funding and is not very feasible.  We 
chose the direct rating approach with partial functions for feasibility, ease of interpretability 
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and the type of model inputs we used in the MCDA model. Once these alternatives were 
scored, these were weighted using the swing weighting approach. Similar to scoring, AHP 
and MACBETH can also be used for weighting however due to our type of model inputs 
we decided to use swing weighting. Swing weighting also allows integrating scores while 
assigning weights where highest weight is assigned to the criterion that would improve the 
overall value of the alternative the most on swinging from its worst to best score. 37 Another 
technique used for weighting is SMARTER ranking technique that weights the criteria 
irrespective of the score assigned. 37 However, when the scores have been assigned using 
direct rating by considering the worst and the best value (partial functions), it is preferable 
to use swing weighting that considers the worst and the best value as well. An example of 
swing weighting would be as follows which shows that swinging the scale of cardiovascular 
mortality from 36 (worst value) to 0 (best value) might be more important than swinging 
the scale for overall survival from 40.8 (worst value) to 59.3 (best value) based on literature 
inputs: 
 
     
 
 
 
Aggregate scores were back calculated using the additive model to assign a value 
for each of the alternatives. Following is the function that was used to assign value using 
the additive model: 
Vj = ∑ Sij . Wi  (V = overall value, S = score, W = weight) 
Cardiovascular 
Mortality 
0 
 
36 
Overall 
Survival 
 
59.3 
 
          40.8 
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Scores, weights and aggregate values per alternatives were estimated using the 
MS Excel, 1000minds MCDA software and RStudio.38,39 We used MS Excel to create the 
performance tables that were then pulled into R for analyses. Minimum and maximum 
values for each of the criteria were specified (maximum as the best for benefits and 
minimum as the best for risks) on R. The MCDA package on R then assigns a score of 1 
to the maximum value of criterion across the therapy regimens, and others are then scored 
and normalized with respect to the best value. 39 These assigned scores are summarized 
below in Table 32. Once normalized and scored, each criterion was then weighted using 
the relative importance values obtained from 1000minds by assigning a negative weight 
to risks and positive weight to benefits. To assign these weights 1000minds provides a 
series of comparisons between criteria. For each comparison, we picked the criteria that 
we considered would be more valuable with respect to swinging the score from worst to 
best based on literature inputs. All the comparisons were then aggregated to estimate a 
criterion preference value (Figure 23 below) by 1000minds software that was then used to 
assign weight manually on R (Table 33 below).  These were then ranked on R by 
aggregating scores and weights and assigning a quantitative value to each alternative. 
These overall generated values were then compared for alternatives prespecified in the 
MCDA model. 13,37-44 This entire process of developing the MCDA model has been 
summarized in Figure 21 below. 
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Figure 21: Process Of Developing MCDA Model 
 
Aim 2c: To conduct sensitivity analyses to assess the model performance and 
uncertainty in the model 
 Sensitivity analyses were conducted using ranges from literature for the parameter 
inputs to assess uncertainty in the model. These ranges were confidence intervals that 
were reported in the studies mentioned above in Table 25 for certain criteria within specific 
therapy alternative. Ranges for parameter inputs such as overall survival, cardiovascular  
hospitalization and any other cardiovascular event were used. The inputs from Table 26 
Deciding HER 2 positive breast cancer therapy regimens 
Selecting and structuring the benefits and risks criteria influenced by literature 
Measuring performance of each therapy regiment using model inputs from the 
literature for each criterion 
Scoring using direct rating approach with partial functions (R MCDA package) 
Weighting using swing weighting (1000Minds MCDA software) 
Aggregating (R MCDA package) 
Therapy regimen ranking (R MCDA package) 
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were used as the base case values whereas the inputs from Table 27 were used for the 
sensitivity analyses. One parameter was changed at a time to assess the impact on the 
outcome. We replaced one base value at a time in the performance Table 26 by values 
mentioned in Table 27  to assess its effects on preferences for therapy regimens. The 
results of the sensitivity analyses were used to make conclusions about the uncertainty of 
the model and the parameters that affect the model the most. Along with using the values 
from Table 37, we also used certain different sets of weights to weight these criteria 
differently and assess the effects on therapy alternative ranking. The results for therapy 
ranking with different sets of weights tried have been summarized in the ‘Results’ section 
below. All these values were derived from the literature.  
Table 27: Values Used for Sensitivity Analyses of The MCDA Model 
 
 
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
      NA*  - Not available 
                   Regimen 1: Trastuzumab + taxane 
                   Regimen 2: Trastuzumab + Pertuzumab + taxane 
                   Regimen 3: Trastuzumab + Cyclophosphamide/Carboplatin + taxane 
   
 
 
Criteria Sensitivity analyses 
values 
Overall survival (months)26,27 
Regimen 1 
Regimen 2 
Regimen 3 
 
35.8, 48.3 
49.3, NA* 
NA 
Cardiovascular hospitalization (%)30-32 
Regimen 1 
Regimen 2 
Regimen 3 
 
1.7, 5.4 
NA 
34, 77 
Any other cardiovascular event (%)30,31,33 
Regimen 1 
Regimen 2 
Regimen 3 
 
0.1, 1.8 
NA 
1.6, 4.1 
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RESULTS: 
Aim 2A: To describe the cancer therapy characteristics associated with the 
cardiotoxic adverse events and evaluate the drug-event association using a 
disproportionality analysis 
 There were 35,630,544 adverse events reported in breast cancer patients identified 
from FAERS 2005-2015 files. In the FAERS data we found that, of those receiving targeted 
breast cancer therapy, 3.82% reported events were a cardiotoxic adverse event as 
compared to 3.46% in the non-targeted therapy group. Majority of cardiotoxic adverse 
events reported on FAERS were at an initial visit. In majority of the cases, the targeted 
therapy drug was a primary suspect and was reported by the physician. The route of 
administration in majority of the cases was ‘Oral’ followed by ‘Others’ which mainly 
comprised of subcutaneous and intraperitoneal along with some other categories. These 
descriptive characteristics of events reported on FAERS have been reported in Table 28 
below. We did not report the dosage related characteristics and  rechallenge/ dechallenge 
characteristics since the proportion of missing values in these was more than 90%. 
Table 28:Descriptive Characteristics Associated with Cardiotoxic Events in Breast 
Cancer Patients in the US From FAERS 2005-2015 files 
 
Characteristics Cardiotoxic event 
N(row%, column%) 
1,234,823 (3.47) 
 
No cardiotoxic event 
N(row%, column%) 
34,395,721 (96.53) 
Gender 
Females 
Neutral 
Missing 
 
629,926 (3.06, 51.01) 
398 (0.14, 0.03) 
604,499 (4.08, 48.96) 
 
19,920,000 (96.94, 57.93) 
280,435 (99.86, 0.85) 
14,195,933 (95.91, 41.22) 
Age, in years (mean) 45.8 54.8 
Time of visit 
Initial visit 
 
590,384 (2.97, 47.81) 
 
19,290,000 (97.03, 56.08) 
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Follow up visit 
Missing 
644,419 (4.09, 52.19) 
0 (0) 
15,100,000 (95.91, 43.91) 
5,017 (0.01) 
Role of the drug 
Interacting drug 
Primary suspect 
Secondary suspect 
Concomitant 
Missing 
 
2,434 (2.05, 0.20) 
417,106 (3.39, 33.78) 
192,389 (2.89, 15.58) 
622,894 (3.76, 50.44) 
0 (0) 
 
116,052 (97.95, 0.34) 
11,870,000 (96.61, 34.51) 
6,475,129 (97.11, 18.83) 
15,920,000 (96.24, 46.30) 
10,707 (0.03) 
Occupation of the reporter 
Lawyer 
Physician 
Other health professional 
Pharmacist 
Registered nurse 
Consumer 
Missing 
 
130,022 (9.68, 10.53) 
430,611 (4.19, 34.87) 
222,937 (3.46, 18.05) 
50,652 (3.08, 4.10) 
9 (0.02, 0) 
253,811 (2.04, 20.55) 
146,781 (4.26, 11.89) 
 
1,212,530 (90.32, 3.53) 
9,852,746 (95.81, 28.65) 
6,223,498 (96.54, 18.09) 
1,595,841 (96.92, 4.64) 
40,546 (99.98, 0.12) 
12,170,000 (97.96, 35.39) 
3,297,233 (95.74, 9.59) 
Route of administration 
Oral 
Parenteral 
Respiratory 
Rectal/Vaginal 
Topical 
Others 
Missing 
 
389,933 (4.09, 31.58) 
1,036 (3.53, 0.08) 
8,917 (2.44, 0.72) 
1,919 (2.68, 0.16) 
37,880 (2.23, 3.07) 
121,220 (2.96, 9.82) 
673,918 (6.5, 54.58) 
 
9,145,221 (95.91, 26.59) 
28,329 (96.47, 0.08) 
356,855 (97.56, 1.04) 
69,755 (97.32, 0.20) 
1,658,865 (97.77, 4.82) 
3,969,386 (97.04, 11.54) 
19,162,313 (93.5, 55.73) 
Adverse event outcome 
Death 
Life-Threatening 
Hospitalization 
Disability 
Congenital Anomaly 
Required Intervention 
Other serious events 
Missing 
 
142,064 (6.26, 11.50) 
72,911 (6.98, 5.90) 
505,101 (5.34, 40.90) 
21,229 (2.70, 1.72) 
14,479 (10.61, 1.17) 
9,212 (3.63, 0.75) 
427,455 (3.33, 34.62) 
42,372 (0.48, 3.43) 
 
2,126,695 (93.74, 6.18) 
971,642 (93.02, 2.82) 
8,947,317 (94.66, 26.01) 
765,364 (97.30, 2.23) 
121,993 (89.39, 0.35) 
244,274 (96.37, 0.71) 
12,410,000 (96.67, 36.07) 
8,811,590 (99.52, 25.62) 
Therapy duration 
< 1 Day 
Days 
Weeks 
Months 
Years 
Missing 
 
7,826 (4.66, 0.63) 
135,107 (5.73, 10.94) 
5,643 (3.54, 0.46) 
18,111 (7.05, 1.47) 
18,186 (5.12, 1.47) 
1,049,950 (3.25, 85.03) 
 
159,948 (95.34, 0.47) 
2,224,555 (94.27, 6.47) 
153,895 (96.46, 0.45) 
238,817 (92.95, 0.69) 
337,177 (94.88, 0.98) 
31,280,760 (96.75, 90.94) 
 
Disproportionality approach was used to evaluate the drug-event association 
between targeted therapy and a cardiotoxic adverse event in breast cancer patients 
identified using FAERS files. A 2x2 table of targeted therapy and CVD outcome (Table 29) 
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was created to calculate the odds ratios. Since we are looking at a specific targeted drug 
and adverse event pair, these would be denoted as reporting odds ratio in this case. The 
disproportionality approach thus uses the reporting odds ratios obtained from binomial 
logistic regression.  
Table 29: 2x2 Table for Those Reporting A Cardiovascular Adverse Event Across 
The Breast Cancer Therapy Groups in the US From FAERS 2005-2015 files 
 
Targeted therapy 
Yes No 
 
CVD 
Yes 7,173 1,227,650 
No 180,375 34,215,346 
 
The following unadjusted odds ratios reported in Table 30 were obtained for the 
association between targeted therapy and the odds of cardiovascular adverse event. 
These results suggest that in the FAERS database, the patients who received targeted 
therapy had higher odds of reporting a cardiovascular adverse event as compared to those 
with no targeted therapy. This effect was however not  
Table 30: Unadjusted Reporting Odds Ratios for the Association Between 
Targeted Therapy And Cardiovascular Adverse Event In Breast Cancer Patients in 
the US From FAERS 2005-2015 files 
Odds Ratio Estimates 
Effect Point Estimate 95% Wald 
Confidence Limits 
Received targeted therapy 1.108 1.082 1.135 
No targeted therapy Reference Reference Reference 
 
Those receiving targeted therapies as identified from the FAERS dataset were 
1.108 times more likely be diagnosed with a cardiovascular adverse event as compared 
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to those without a targeted therapy. These results were then adjusted for age, time of visit 
(initial visit/ follow up), role of the drug, occupation of the reporter, duration of the therapy, 
route of administration and severity of the adverse event. On accounting for other factors 
identified using FAERS, it was found that those receiving a targeted therapy  were more 
likely to be diagnosed with a cardiovascular event as compared to those who were not. 
These results are reported below in Table 31. 
Table 31: Reporting Odds Ratios on Adjusting for Other Covariates Identified from 
the FAERS 2005-2015 Files 
Odds Ratio Estimates 
Effect Point Estimate 95% Wald 
Confidence Limits 
Targeted therapy 
Received targeted therapy 1.042 1.014 1.071 
No targeted therapy Reference Reference Reference 
Age 
Age 1.000 1.000 1.000 
Time of visit 
Initial visit 0.926 0.922 0.930 
Missing 1.764 1.032 3.013 
Follow up Reference Reference Reference 
Role of the drug 
Interacting drug 0.533 0.509 0.557 
Primary suspect 1.122 1.116 1.128 
Secondary suspect 0.771 0.767 0.776 
Concomitant Reference Reference Reference 
Occupation of the reporter 
Lawyer 3.157 3.129 3.185 
Physician 1.272 1.265 1.280 
Other health professional 1.077 1.069 1.084 
Pharmacist 0.964 0.954 0.975 
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Registered nurse 0.008 0.004 0.016 
Missing 1.332 1.322 1.342 
Consumer Reference Reference Reference 
Duration of the therapy 
<1 Day 0.793 0.773 0.814 
Weeks 0.774 0.751 0.798 
Months 1.392 1.368 1.417 
Years 1.063 1.044 1.081 
Missing <0.001 <0.001 >999.999 
Days Reference Reference Reference 
Route of administration 
Parenteral 0.829 0.775 0.887 
Respiratory 0.902 0.880 0.924 
Rectal/Vaginal 0.913 0.868 0.961 
Topical 0.700 0.691 0.709 
Others 0.802 0.796 0.808 
Missing 0.888 0.882 0.895 
Oral Reference Reference Reference 
Adverse Event Outcome 
Death 1.242 1.233 1.250 
Life-Threatening 1.279 1.268 1.290 
Disability 0.446 0.439 0.453 
Congenital Anomaly 2.479 2.415 2.545 
Required Intervention 0.668 0.653 0.684 
Other serious events 0.572 0.569 0.575 
Hospitalization Reference Reference Reference 
The probability modeled in the logistic regression above was reporting a 
                           cardiovascular adverse event 
                          All the above covariates except age were significant predictors as per FAERS data 
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We can see from the results obtained above using FAERS files that targeted 
therapy was associated with cardiotoxic adverse events with patients receiving targeted 
therapy being more likely to be diagnosed with a cardiotoxic adverse event (adjusted OR 
= 1.042, 95% CI : 1.014, 1.071). However, it can be observed from the confidence interval 
that the effect size was not that high since the interval and the point estimate were very 
close to 1. The point estimated obtained on adjusting for other covariates was closer to 1 
than unadjusted (1.042 vs 1.108) suggesting that the association might not be significant 
on accounting for other covariates identified using FAERS 2005-2015 dataset.  
Aim 2b: To develop a MCDA model to conduct benefit-risk assessment of breast 
cancer therapies 
 An MCDA model was built using breast cancer therapy regimens as the alternatives 
among breast cancer patients. This model was built from a benefits-risks perspective to 
assign a quantitative value to each therapy regimen and rank these. There were ten 
studies identified from the literature (Table 25) that were used to generate model inputs 
for the MCDA model. These model inputs from the performance table are represented 
graphically in Figure 22 below to make data visualization easier. This figure suggests that 
regimens 1 and 3 performed the best on most of the benefits criteria (highest score) and 
risks criteria (lowest score).  
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Abbreviations: OS – Overall Survival, PFS – Progression free survival, QALY – Quality Adjusted Life Years, 
CM – Cardiovascular mortality, CH – Cardiovascular Hospitalizations, CE – Cardiovascular events, D – 
Diarrhea, PN – Peripheral Neuropathy, FN – Febrile Neutropenia 
Regimen 1 (R1): Trastuzumab + taxane 
Regimen 2 (R2): Trastuzumab + Pertuzumab + taxane 
Regimen 3 (R3): Trastuzumab + Cyclophosphamide/Carboplatin + taxane 
 
Figure 22: Performance of HER 2 positive Therapy Regimen Alternatives on Each Criterion 
of the MCDA Model Identified From the Literature  
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Like mentioned above, we used partial function scoring technique to assign scores 
to the criteria. This uses values identified from the literature that have been entered in the 
performance table to assign scores. We loaded the performance table onto R, the MCDA 
package preloaded then normalized these values to convert them into scores. Table 32 
below summarizes these scores that were assigned to each criterion for each treatment 
alternative. 
Table 32: Scores Assigned To Criteria Used In The MCDA Model for HER 2 positive 
Therapy Regimen Alternatives 
Criteria Regimen 1 Regimen 2 Regimen 3 
Overall Survival 0.688 0.9527 1 
Progression-free survival 0.9314 0.8345 1 
QALY 1 0.9628 0.9288 
Cardiovascular mortality 0.8055 1 0 
Cardiovascular hospitalization 0.0524 0.2622 1 
Any other cardiovascular event 0.0277 1 0.1555 
Diarrhea 0.7288 1 0.9152 
Peripheral neuropathy 0.2339 1 0.2142 
Febrile neutropenia 0.5384 1 0.3461 
 QALY – Quality Adjusted Life Years indicative of quality of life 
 
    These assigned scores were then used to plot the following radar plots as seen in 
Figure 23. We specified for each benefits criterion (overall survival, progression-free 
survival and QALY) that higher the score better the performance whereas for the remaining 
risks criteria higher the score lower the performance. The radar plots then take this into 
consideration to highlight for each treatment alternative it’s best performance criteria. The 
radar plots suggest that regimen 1 thus performs the best on QALY (highest score), 
diarrhea (lowest score) and cardiovascular hospitalizations (lowest score). Similarly, 
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regimen 2 performs relatively better on overall survival whereas regimen 3 performs the 
best on progression free survival, overall survival and cardiovascular mortality.  
 
 
  Regimen 1: Trastuzumab + taxane 
  Regimen 2: Trastuzumab + Pertuzumab + taxane 
  Regimen 3: Trastuzumab + Cyclophosphamide/Carboplatin + taxane 
Figure 23: Radar Plots For Each HER 2 positive Therapy Regimen Alternative of the MCDA 
Model Using Literature Inputs And Scores Assigned 
 
 
These criteria were then run through the 1000minds software to assign relative 
importance values to each criteria. The software generated criterion preference values as 
seen in Figure 24 below. Higher criterion preference value suggested that cardiovascular 
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mortality was ranked the most important criteria while considering the tradeoff between 
the breast cancer therapy regimens followed by overall and progression-free survival. The 
1000minds software provides pairwise comparisons of these criteria to assess which 
criteria you would consider to be more important to swing the score from worst to best in 
relation to its comparator. On providing these multiple comparisons the software calculated 
that cardiovascular mortality was picked 31% times over its comparator to swing the score, 
which was the highest. The relative importance of cardiovascular mortality was thus the 
highest. The decision to pick one over the other was just based of physician preferences 
in the literature.2,12,45,46 Febrile neutropenia was considered the least important criterion 
while making trade-offs between the breast cancer therapy regimen.  
 
Figure 24: Criterion Preference Values Representing the Relative Importance of Criteria In 
the MCDA Model 
 
 The criterion value functions plot in Figure 25 below was obtained on plotting the 
preference values of each of the criterion. We had 3 levels for each criterion since we were 
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comparing 3 treatment alternatives. Each criterion thus had 3 score values for each 
therapy regimen. The lowest score indicating the lowest level where as the highest score 
indicating highest level. The criterion value functions/ preference values in Figure 24 
indicate that the preference for all the criteria at level 1 is the lowest and it relatively goes 
on increasing as the criteria performs better (level increases) with that for cardiovascular 
mortality being the highest. This plot suggests that the marginal importance of 
cardiovascular mortality was constantly increasing and the highest across all levels of 
criteria for all the alternatives from its lowest score (lowest level) to its highest score 
(highest level). Febrile neutropenia had the lowest marginal importance relative to others. 
 
Figure 25: Criterion Value Functions Across the Therapy Regimen Alternatives 
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 The following Figure 26 summarizes the relative importance of each criterion in 
relation to each other specific criterion. It suggests that cardiovascular mortality is 1.5 
times more important than overall survival and so on.  
 
Figure 26: Criterion Preference Values Representing the Relative Importance of Criteria In 
the MCDA Model 
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 The criterion preference values like those obtained in Figure 24 above were 
used to assign weights on R by converting them into probabilities. Cardiovascular mortality 
having the highest weight of 0.315 with others following in the same order. For the risks 
criteria, the absolute values of the assigned weights were considered however they were 
denoted by a negative sign as per the MCDA package requirements to signify unfavorable 
effects. To account for uncertainty in these preference values, weights were changed and 
included in the sensitivity analyses as well. The base values used for  weights have been 
summarized in Table 33 below. 
Table 33: Weights Assigned To Criteria Used In The MCDA Model 
Criteria Assigned Weights 
Overall Survival 0.206 
Progression-Free Survival 0.134 
QALY* 0.056 
Cardiovascular Mortality -0.315 
Cardiovascular Hospitalization -0.0605 
Any Other Cardiovascular Event -0.104 
Diarrhea -0.069 
Peripheral Neuropathy -0.041 
Febrile Neutropenia -0.009 
      *QALY – Quality Adjusted Life Years indicative of quality of life 
 
On aggregating the scores and weights assigned to each criterion, the alternatives 
were ranked in the following order as per the value assigned to these. 
Preference 1: Therapy regimen 3 (Trastuzumab + Cyclophosphamide/Carboplatin 
+ taxane) 
Preference 2: Therapy regimen 1 (Trastuzumab + taxane) 
Preference 3: Therapy regimen 2 (Trastuzumab + Pertuzumab + taxane) 
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  These preference rankings were derived based on the inputs we obtained from the 
literature. On applying these to real world these might not hold true since the population 
might have certain differences. We chose studies for model inputs that had similar 
population to avoid any biases. However, in a real world setting HER 2 positive breast 
cancer patients might not be as alike and might be on different therapy regimens in addition 
to those considered in our MCDA model. The decision-making framework might thus need 
to be revised by adding more inputs and data from the real world to be applicable on a 
broader scale and result into changes in guidelines. Our preference rankings are however 
a good starting point to showcase the application of a formal decision-making model in a 
multidisciplinary field like oncology. Currently there is no clear consensus on the 
preferences and physician suggest using trastuzumab with any other chemotherapy drug 
(taxane or cyclophosphamide/ carboplatin) or pertuzumab as the first line treatment.20,47 
Our study might help in narrowing down these broad categories to specific therapy 
regimens and might add to the current practice guidelines to make it more specific. The 
treatment alternatives we included in our model were all first-line options and there has 
not been an attempt in the literature earlier to look at each of these specific regimens and 
weigh out the benefits and risk associated with each. Earlier guidelines have looked at 
trastuzumab along with chemotherapy as a whole. Our  results help in further narrowing 
down those chemotherapy options and therapy regimens based on preferences to make 
decision-making more transparent. The treatment landscape of HER 2 positive breast 
cancer is constantly growing and emerging, studies like ours can help in navigating the 
landscape better by assigning rankings and narrowing down the options.  
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Aim 2c: To conduct sensitivity analyses to assess the model performance and 
uncertainty in the model 
 We conducted sensitivity analyses to assess for model robustness and the 
uncertainty involved. We used values from Tables 27 and 34 to check if the model was 
sensitive to any of these and if the therapy regimen preference ranking changed on 
changing any of these values as compared to the base case values (Tables 26 and 33).  
We changed one performance value at a time from Table 27 by keeping the rest same 
and assessed the model output. Like mentioned above, these performance values 
summarized in Table 27 were identified from the literature. The confidence intervals were 
available in the literature for overall survival, cardiovascular hospitalization, and 
cardiovascular events. These criteria were thus used in sensitivity analyses. We observed 
that our model was robust to any of these changes in the criteria performance values. We 
obtained the same results with the same therapy regimen ranking on changing the base 
case value to any of the values mentioned in Table 27. The model was also robust to most 
of the weight changes mentioned in Table 34 below. We kept the same base case values 
for the performance matrix although changed the criteria weights for this analysis. We 
used four different sets of weights. In set 1 we kept all the other weights same, although 
weighted overall survival higher than the cardiovascular mortality given the trade-off 
between these decisions. 2,12,45,46 The remaining sets of weights were based on a ‘trial and 
error’ methodology to assess the effects on therapy ranking. In set 2 we weighted overall 
survival as high as cardiovascular mortality with others relatively lower. In set 3 we 
weighted all the benefits criteria higher than risks whereas in set 4 we weighted all the 
risks criteria higher than benefits.  These weights were not driven by literature sources but 
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based on general understanding. We had similar therapy regimen ranking with sets 1, 2 
and 3 of weights. Although on weighting all the unfavorable effects higher than the 
favorable effects, the ranking of the alternatives changed a little bit. Therapy regimen 1 
with a trastuzumab and taxane was now ranked the highest as the most preferred regimen 
followed by therapy regimen 3 with trastuzumab, cyclophosphamide/ carboplatin and a 
taxane. The least preferred alternative was therapy regimen 2 with trastuzumab, 
pertuzumab and a taxane. These results have been summarized in Table 34 below.  
Table 34:Different Sets Of Weights Used To Conduct Sensitivity Analyses To 
Assess The Robustness Of The MCDA Model 
 
Model criteria Weights 1 Weights 2 Weights 3 Weights 4 
Overall survival 0.315 1 1 0.5 
Progression-free 
survival 0.134 0.75 1 0.5 
QALY* 0.056 0.5 1 0.5 
Cardiovascular 
mortality -0.206 -1 -0.5 -1 
Cardiovascular 
hospitalization -0.0605 -0.75 -0.5 -1 
Any other 
cardiovascular 
event -0.104 -0.5 -0.5 -1 
Diarrhea -0.069 -0.25 -0.5 -1 
Peripheral 
Neuropathy -0.041 -0.25 -0.5 -1 
Febrile 
Neutropenia -0.009 -0.25 -0.5 -1 
Therapy 
Ranking 
R3a - 1, R1b - 2, 
R2c - 3 (no 
change) 
R3 - 1, R1 - 2, 
R2 - 3 (no 
change) 
R3 - 1, R1 - 2, 
R2 - 3 (no 
change) 
R1 - 1, R3 - 2, 
R2 - 3 
(changed) 
*QALY – Quality Adjusted Life Years indicative of quality of life 
a R1 – Therapy Regimen 3 (Trastuzumab + Cyclophosphamide/Carboplatin + taxane) 
b R2 – Therapy Regimen 1 (Trastuzumab + taxane) 
c R3 – Therapy Regimen 2 (Trastuzumab + Pertuzumab + taxane) 
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DISCUSSION: 
 Our findings suggest that based on FAERS data breast cancer patients receiving 
targeted therapies were more likely to be diagnosed with a cardiovascular event as 
compared to those who were receiving conventional therapies. These results were 
adjusted for age, time of visit, occupation of the reporter, therapy duration, route of 
administration and the severity of the outcomes. However, as mentioned in the results 
earlier the effect size was small on adjusting for confounding factors and the confidence 
intervals closer to 1. This suggests that on controlling for other factors observed in FAERS 
data, this association might not be clinically relevant. Although statistically significant, this 
could have low clinical utility and more data would be required to make any more 
conclusions.  
On conducting multicriteria decision analysis, we found that the breast cancer 
therapy with Trastuzumab, cyclophosphamide/ carboplatin and a taxane (paclitaxel/ 
docetaxel) was the most preferred therapy alternative given the benefits and the risks 
associated with each of the alternatives. Therapy regimen containing Trastuzumab, 
Pertuzumab and a taxane (paclitaxel/ docetaxel) was the least preferred alternative. The 
most important criteria considered in the decision making was cardiovascular mortality 
followed by overall survival. This is reflective of physicians and oncologists starting to get 
more worried about the side effects of these therapies along with the cancer outcomes of 
the patients.2,12,45,46  This could also be the reason for therapy regimen 2 with two targeted 
therapies (trastuzumab and pertuzumab) being the least preferred regimen. Since 
targeted therapies have higher cardiovascular implications, adding two targeted therapies 
to a regimen can further increase the risk of CVD and down the line can become the least 
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preferred regimen when compared to others.8 Currently physicians prescribe treatment 
based on the clinical factors associated with the tumor type with the goal of prolonging life 
span.21,47 With cardiovascular mortality increasing in cancer patients, the goal of 
prolonging lifespan would not only depend on the tumor type but also on cardiovascular 
implications. It has been suggested in the literature that clinicians need to be aware about 
the cardiovascular consequences of certain types of cancers and cancer therapies to have 
a better coordinated cardiovascular care where the cancer treatment planning can limit 
the use of targeted therapies.34 Currently, physicians encourage any trastuzumab based 
therapy usually coupled with another chemotherapy drug (could be an alkylating agent like 
carboplatin/ cyclophosphamide or a taxane like paclitaxel/docetaxel).47 Our study helps in 
narrowing down these treatment regimen options  to specific chemotherapy drugs used. 
NCCN enlists the treatment guidelines for HER 2 positive breast cancer patients although 
they do not assess preferences within these.14 Our study helps in assigning a preferential 
ranking to these regimens give the inputs on criteria we included in our study. Stating the 
criteria we considered, and weights used upfront helps in making this decision-making 
process more transparent by informing the stakeholders (providers in our case) about our 
approach.15 The providers can then revise this model as per their needs by adding more 
criteria and changing the weights to make the model more generalizable. This guided 
approach would help in treatment planning especially with multidisciplinary teams involved 
where everyone could weigh in on the model inputs. Our study sets up a basic MCDA 
model that can further be revised by adding more criteria as evidence gets available to be 
utilized in the real-world. If the data is available, more alternatives for decision-making 
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such as surgery, radiotherapy, other treatment regimens can also be added to this model 
to further make it more applicable. 
A study conducted by Scherrer et al. looked at sequential decision making using a 
multicriteria decision modelling in breast cancer therapy planning.35 This study suggested 
that the novel decision-making approach was more efficient in clinical decision making. 
The authors stated that the model facilitated the establishing of a rule-based system, which 
encodes medical knowledge of treatment options originating from various sources in a 
precise and reliable way. This process was time-efficient in making decisions and 
treatment planning, which addressed the time shortage issue in clinical routine mentioned 
by the authors. This study was however restricted to case studies of few patients and thus 
was not generalizable to the entire population. In addition, this study focuses more on 
breast cancer therapy planning taking into consideration number of physician visits, 
frequency of medication, etc.35 Our study however compares therapy regimens used in 
breast cancer patients from a benefit-risk perspective. The previous study focuses more 
on problems that are consistent with planning the treatment that involve diagnosis timeline, 
physician visits, etc. rather than focusing on the therapy alternatives to choose from. Our 
study is more specific to therapy alternatives that are available for physicians to choose 
from. We incorporated risks and benefits outcomes associated with each regimen in our 
model where as the prior study just looked at treatment as one of their criteria and not an 
alternative. The prior study gives an idea of how efficiently the physicians can plan the 
treatment with respect to the timeline to be more efficient whereas our study gives an idea 
of which treatment to choose from given the available options in our model.  
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Another study conducted by  Lin et al. looked at physician experiences and 
preferences in the treatment of HER 2 negative breast cancer patients. Since this study 
focused on HER 2 negative patients, their treatment options were different. Treatment 
preferences were collected by class of endocrine therapy-based regimens versus 
chemotherapy. This study did not use the MCDA approach, they only looked at survey-
based responses by physicians to treatment preferences. The findings suggest that 
physicians used anastrozole most frequently, followed by everolimus - based therapy 
followed by fulvestrant-based therapy. Efficacy was the most important consideration for 
treatment choices followed by tolerability, quality of life and cost of drug in that order. This 
study however only used a survey - based approach to evaluate current physician 
preferences to be considered while making a treatment choice.12 This would help in 
assigning weights to the criteria, although our study looks at performance of therapy 
alternatives on prespecified criteria to rank the regimens. We used literature inputs to 
assess the performance to then assign value to each regimen. In addition, our study was 
focused on HER 2 positive breast cancer patients.  
Another study conducted by DeKoven et al. also looked at treatment patterns for 
HER 2 positive breast cancer patients. The findings of this study suggested that 
trastuzumab-based regimens were the preferred option for treating HER 2 positive 
metastatic breast cancer patients. However, this was also a survey-based study where 
practicing oncologists were surveyed to identify breast cancer patients and their 
treatments. The preferred regimen was evaluated based on the biomarker status. This 
study also did not look at specific regimens but trastuzumab-based regimens as a whole. 
Our study however looked at specific HER 2 positive breast cancer treatment regimens.48 
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The prior study was also not conducted from a decision-making perspective rather to just 
evaluate treatment patterns. Our study helps in decision-making by scoring and weighting 
criteria using literature inputs and rank the therapy regimens. 
Our study has many strengths. Firstly, this is one of the first studies that has been 
conducted in the literature that has applied an MCDA technique to aid formal decision 
making from a benefit-risk perspective of cancer therapies. The MCDA studies that have 
been conducted so far in the literature have mainly been from a patient perspective 
involving shared decision making between the patient and the physician.7 - 9 These have 
only looked at patient preferences and satisfaction in order to make a decision. Our study, 
however, takes into consideration some of the clinical outcomes associated with these 
therapy regimens that makes comparison of these regimens more formal from a benefit-
risk perspective. Secondly, there have been studies in the literature that have individually 
looked at benefits and risks associated with these therapy regimens or individual targeted 
drugs. This is one of the first studies that consolidates the beneficial and adverse 
outcomes of cancer therapy regimens together in a single model to assign a value to each 
of these regimens. The previous studies that have been conducted with a benefit-risk 
perspective have been in non-cancer population.40-43 Thirdly, given the growing concerns 
associated with the adverse effects of these therapy regimens our findings provide a 
guided formal decision-making model. They help in choosing one treatment over the other 
based on the criteria considered in our model and the performance of alternatives on these 
identified from the literature. Given the growth in research with respect to oncology 
treatments, the decision-making would get more and more difficult with increasing options. 
A guided approach like this would thus be necessary in making value trade-offs. Our study 
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also creates radar plots for each therapy regimen to show the criteria it performs the best 
on. These findings would inform the physicians about the criteria to consider while 
choosing between these regimens. Based on the criteria the regimen performed the worst 
on, physicians can be more cautious about these while prescribing. It also informs 
physicians about the criteria we considered while making the decision. If any physician 
has different criteria that they might consider important, based on the inputs of each 
alternative for these criteria the ranking of the alternatives might change. This model can 
then be revised and tailored to fit the physician’s needs to include more criteria and inputs 
on these to make it more applicable in the real world.  
 However, our study also has major limitations. Firstly, FAERS only captures 
information on adverse events that were reported. Based on literature there is high under 
reporting of spontaneous adverse events.49 Given that targeted therapies such as 
trastuzumab are first line agents, it is possible that there were more events associated with 
these although were not reported on FAERS. This should be considered while interpreting 
odds ratios. This underreporting could have also been the reason for smaller effect sizes. 
This underreporting might limit generalizability and  lower validity of the study due to some 
misclassification and information bias. FAERS also does not capture demographics 
extensively and thus there could be some confounding effect in the relationship of 
likelihood of being diagnosed with CVD and receiving targeted therapies. It is possible that 
certain demographics factors such as race and employment status could affect access to 
care and hence affect receipt of targeted therapy and diagnosis of cardiotoxic events as 
well. This however could not be controlled for in our study due to data limitations. Additional 
data on dosage related characteristics might have also helped in characterizing the cancer 
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treatment related factors further to help in tailoring these as per patient needs. Secondly, 
the studies included in the MCDA model were done in slightly different populations which 
could bias the results to some extent by making the groups not equal in comparison. This 
would however be reduced since we used a strict inclusion/ exclusion criterion to identify 
studies that would provide the model inputs to maintain uniformity. We restricted our 
studies to those that looked at HER 2 positive breast cancer patients. However slight 
differences in their biomarkers existed which might have an impact on the outcome. In this 
case the model inputs might have been a result of the type of their biomarker rather than 
the therapy alternative. Although, we also used sensitivity analyses that would assess the 
robustness and uncertainty of the model to a range of model inputs to reduce this further. 
Thirdly, due to lack of evidence across all the therapy regimens, we could only consider 
criteria that we had evidence on and were consistent across all the alternatives. On gaining 
additional evidence on some more criteria that the physicians might consider important, 
the ranking of therapy regimens might be altered. In addition, due to limited availability in 
the literature, we had to select some criteria such as overall survival and QALY as a 
substitute for quality of life which might not completely be nonoverlapping. However, QALY 
was the only measure of quality of life that was reported well in the literature. Progression-
free survival might also overlap with overall survival, however in our studies overall survival 
was measured in months whereas progression-free survival was measured as proportion 
of patients who were progression-free which might reduce this overlap. Thus, due to 
limited literature evidence, we could not keep our benefits criteria completely 
nonoverlapping. Including more data on long term outcomes of these therapies by 
conducting a longitudinal study in the future might also help in making the model more 
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generalizable for the real-world. Revising the model can then lead to different preferential 
rankings between therapies. It is however one of the first studies conducted using an 
MCDA approach for formal decision making and will inform certain future studies.  
 Despite the study limitations, the novelty of the methodology and the implications 
add to the literature. It demonstrated the application of a decision-making methodology in 
oncology care. With further updates to the model, it can be used in a real-world setting to 
make decisions and impact the current treatment guidelines.   As mentioned earlier, since 
cancer treatment requires a multidisciplinary approach, a multicriteria decision analysis 
model would help in making decision-making more formal and transparent. A value 
assessment of breast cancer therapy regimens can serve as a basis for various payment 
policies, clinical treatment selection and development on the part of pharmaceutical 
companies.50 The use  of value-based frameworks in guiding payment policy decisions is 
increasing.51 A study like ours with further revisions, can help in making certain policy 
decisions by reimbursing the therapy regimen that is ranked as the most preferred regimen 
higher. Treatment ranking can also directly be factored into clinical treatment selection and 
encouraging more discovery from the pharmaceutical companies for similar regimens and 
drugs.  
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CHAPTER 4: CONCLUSION 
 
SUMMARY OF FINDINGS:  
Our project characterized the population with cancer and cardiovascular diseases 
(CVD) both as compared to those only with cancer. We found that mainly patients who 
were younger and employed were less likely to be diagnosed with CVD. Other results 
might have been attributable to a lower sample size and thus have lower power. We then 
evaluated the use of machine learning algorithms in the prediction of cardiovascular risk 
among cancer patients as compared to conventional regression techniques. The machine 
learning models used in our study had higher predictive power as compared to the 
standard regression technique. Out of all the machine learning algorithms that we 
compared; random forest models for acute and chronic CVD were associated with the 
highest c-statistic indicating that they were better in predicting CVD risk in cancer patients. 
We validated these models using internal and external validation techniques. The results 
of these suspected some overfitting involved in the random forest models. We used these 
models to then build the web-based applications predicting probability of chronic and acute 
CVD risk in cancer patients. These applications used the most important predictors that 
were identified by the random forest algorithm. However, given the overfitting issue, the 
models might need to be further revised by calibration and acquiring more data to then 
create applications that can be used in a real-world setting. Future studies in this case to 
evaluate model calibration would help in further increasing the clinical utility of the model. 
Incorporating long term outcomes and additional data from longitudinal files might be 
helpful in increasing the generalizability and thus validity of the models.  
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We then focused on breast cancer patients and described certain cancer therapy 
and adverse event related factors with cardiotoxic adverse events. Targeted therapy was 
a primary suspect in most of the cardiotoxic events with an oral route of administration. 
Adjusted analyses suggested that patients receiving targeted therapy were more likely to 
witness a cardiovascular adverse event. However, the clinical significance of 
thisassociation might be low since the effect size of the odds ratio was small. We also 
evaluated application of multiple criteria decision analysis (MCDA) model to conduct 
benefit-risk assessment of HER 2 positive breast cancer therapy regimens. We conducted 
benefit-risk assessment using MCDA model to score and weight breast cancer therapy 
regimens to rank the most preferred treatment regimen. Given the benefits and  risks 
(other adverse events along with cardiovascular implications) associated with the 
therapies in our MCDA model, the therapy regimen with trastuzumab, 
cyclophosphamide/carboplatin and a taxane was the most preferred regimen. On 
conducting sensitivity analyses, we found that our model was robust to most of the 
changes.   
We thus implemented newer analytical techniques to evaluate certain 
cardiovascular outcomes among cancer patients. Based on our study results, the newer 
techniques showed potential to be used in real-world practice. Due to data limitations, our 
models might not be ready to be used directly in the clinical practice and in the real world, 
although they do suggest that with further revisions, these might help in changing the 
current landscape.  With more data getting available with each day, techniques like 
machine learning can handle the ‘Big Data’ more efficiently than the standard regression 
approaches. Research in oncology treatment planning has also been growing and a 
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decision analytic tool like MCDA model can help in making decision-making easier as more 
options get available. Future research can be encouraged in these fields of machine 
learning and decision analytics to make healthcare more efficient.  
Our study aim 1 has multiple implications. Firstly, characterizing the population that 
has cancer and CVD both would help in understanding the underlying factors responsible 
for putting cancer patients at a higher risk for developing CVD and managing the condition 
more efficiently. Secondly, the use of machine learning algorithms in predicting CVD risk 
would help in identifying future risk of CVD early in cancer patients. Machine learning 
algorithms as suggested above have a good predictive power as compared to the 
regression approaches. Based on the current predictors, the trained model might be able 
to predict a 5 or 10 year CVD risk which can then be utilized by physicians to plan the 
treatment better. Based on the probability of the risk the physicians might consider 
involving a multidisciplinary team with a cardiologist to monitor the cardiac health of cancer 
patients better. It would help in deciding the cancer treatment regimen to reduce the risk 
of acute and chronic CVD events. It would also help in encouraging prophylactic CVD care 
in cancer patients. Currently, the physicians are starting to get more worried about the 
cardiovascular health of cancer patients while planning treatment since the mortality rates 
due to cardiac conditions is increasing in cancer patients.1 - 4 Given the concerns, a 
predictive model like ours with revisions made to it can help in understanding the risk 
earlier in time and planning the treatment accordingly. 
Our study aim 2 also has multiple implications for breast cancer patients. Identifying 
cancer therapy and population characteristics associated with cardiotoxic adverse events 
in breast cancer patients would help in preventing these adverse events in the future. The 
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predictors we identified to be significant such as targeted therapy and route of 
administration can be paid more attention to in mitigating the cardiovascular implications 
on cancer patients. Our MCDA model would help in choosing a specific breast cancer 
therapy regimen given the benefits and the risks associated. MCDA modeling being a 
transparent technique (stating criteria and the weights upfront) of consolidating outcomes, 
it would help in reducing the information asymmetry and guide the decision-making in a 
formal and timely manner. Cancer treatment planning requires a multidisciplinary 
approach. A MCDA model would give a guided approach to all the providers on the 
multidisciplinary team to ease communication and come up with a treatment plan more 
efficiently. Currently there is no guided decision-making approach to cancer treatment 
planning, more studies like ours can help in creating one. Our model includes the criteria 
that we had evidence on, although in the future more criteria can be included in this model 
that might be necessary in decision making to increase the utility of the model that can 
then be used in actual practice.  
FUTURE RESEARCH: 
In our study, we developed machine learning models to  predict the risk of CVD in 
cancer patients. Our model was validated using internal and external validation 
techniques. Our external validation results suggested that there could have been some 
overfitting involved with the random forest model. Future studies can be conducted to 
assess model calibration to further increase the reliability, validity and clinical utility of the 
model.5 - 7 Calibration refers to the agreement of predicted probabilities of a model and 
observed outcomes. It thus evaluates if patients who were predicted to have an event did 
actually have an event down the line. Calibration techniques can help in increasing the 
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validity of the model and the confidence in the predictive power of the model. There are 
multiple calibration techniques such as calibration curves, cost and goodness-of-fit 
functions. Calibration curves are plots of the observed frequency versus the predicted 
frequency, how well these curves overlap is a measure of well calibrated model.8  Cost 
functions on the other hand are the ‘distance’ between the observed and the predicted 
values. Higher the cost function higher is the inaccuracy.9 The goodness-of-fit criteria 
comprises of measures such as sum of squared errors [SSE] and Pearson chi-square 
which quantify the difference between model and observed outcomes.10 Model calibration 
can thus be conducted using any of these techniques. This can be achieved by conducting 
a longitudinal long-term study using healthcare data to evaluate observed outcomes in the 
same patients that were predicted using the model. In order to increase the validity of the 
model, further hypertuning of parameters can be carried out by changing the learning rate, 
number of bootstraps, etc.11 In addition to these algorithms, literature has also suggested 
good performance of some other algorithms such as support vector machines (SVM).12 
SVM is a linear model for classification and regression problems. The algorithm creates a 
line or a hyperplane which separates the data into classes. These can also be built and 
compared against the algorithms already tested in our study. We can also build weighted 
predictive models for predicting CVD risk by using recursive partitioning for modeling 
survey (RPMS) data techniques that can then account for complex sampling survey 
weights.13 These RPMS models allow to input survey weights independent of the 
predictors. With further research these can be used as predictive models too. 
Our MCDA model has ranked preferences for the breast cancer therapy regimens 
based on their benefits and risks involved. Further studies can be conducted to evaluate 
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patient preferences involved in these therapy regimens and incorporate those in the MCDA 
model too. A sample or an expert panel can be used to rank the criteria importance and 
assign weights other than those include in the sensitivity analyses. The criteria can be 
provided as a survey to a sample of physicians to assess the value they would give to 
each criteria and use those as weights. Larger longitudinal databases such as claims files 
can also be used to evaluate the long-term effects of these therapy regimens to be 
incorporated into the model to make the results more generalizable and robust. We used 
criteria in our model that we had available evidence on from the literature. However, if we 
elicit more criteria to be deemed important from the physician perspective, in the future we 
can try to obtain information on these criteria through database analysis and revise the 
model further. Based on evidence, we can also try to include more treatment alternatives 
in the model. A choice based decompositional approach such as a discrete choice 
experiment could also be used in the future to identify more criteria that would be essential 
in decision-making and make the model more robust. In a discrete choice experiment, the 
study sample is provided with the therapy alternatives to choose from. Based on which 
alternative they chose, weights are derived for all the criteria they considered important 
while taking that decision.14 This can be conducted to elicit patient and provider 
preferences both which can then be included in the model to conduct a benefit-risk 
assessment to rank the therapy regimen alternatives using evidence-based approach. 
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